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EXECUTIVE SUMMARY 
Australian injecting drug users are commonly tested for hepatitis C, hepatitis B and 
HIV/AIDS, but while a considerable literature exists in relation to human factors 
involved in testing for HIV/AIDS, there appears to be little or no literature related to 
human factors in testing for hepatitis C and B, or vaccinating against hepatitis B. 
Some studies suggest that being tested is not necessarily a valuable or useful 
experience for individuals and/or that failure to take account of the complex human 
factors involved in testing can either deter individuals from presenting for testing, or 
render testing ineffectual for both the those tested and her/his community. 
In 1997 the NHMRC funded the National Drug Research Institute (NDRI) to conduct 
an investigation of some of the human issues involved in testing injectors for blood 
borne viruses (BBVs) and vaccinating them against hepatitis B. Two hundred injectors 
and 39 test service providers participated in the research. The study showed that the 
process of testing was, in many cases, far from satisfactory and that the only purpose 
served by much of the testing appeared to be the diagnosis of infection and the 
implementation of appropriate medical interventions. This falls well short of the 
intention of NHMRC Guidelines for Pre- and Post-test Counselling for Hepatitis C 
which suggest that the outcomes should be the provision of psychosocial support, 
prevention of the transmission of hepatitis C and the optimisation of treatment 
outcomes. The data suggested that, in the main, only the last of these outcomes was 
being met. Reported low levels of hepatitis B vaccination were also a concern. 
The present study is an examination of clinical and practical difficulties with the 
NHMRC Guidelines. This project aimed to deepen knowledge about the process of 
testing injectors for hepatitis C and other blood borne viral infections and to develop 
concrete recommendations for changes to the Guidelines for pre- and post-test 
counselling. The project was informed at every stage by consultants drawn from a 
range of relevant organisations. The data collection methodology was primarily 
qualitative, using a number of different techniques (interviews, focus groups and 
consultations) to develop a total data set upon which conclusions and 
recommendations were based. 
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There were two phases in the study. In Phase 1, 19 tested injectors and 21 health 
professionals (test service providers and key informants) were interviewed about the 
Guidelines. As part of the interviews, test service providers were presented with two 
scenarios relating to hypothetical requests for BBV tests and asked what they would 
do in each situation. The data from Phase I were discussed by the consultants and 
investigators and led to the development of proposed modifications to the Guidelines.  
In Phase Two, the draft modified guidelines were presented to two focus groups for 
their comments, and their comments were further discussed by the consultants.  
Our final proposals for modifications to the existing NHMRC Guidelines for hepatitis 
C testing have taken as many as possible of these disparate points of view into 
consideration.  We also suggest that the modified guidelines should be generalised to 
all BBV testing with injectors, since most tests occur in batteries rather than singly. 
Our proposed guidelines, therefore, relate to BBV testing with injectors. The proposed 
guidelines are attached at the end of this summary.  
There are a number of other issues which have emerged as concerns and need to be 
addressed:  
 The specific resource needs of rural/regional test service providers (TSPs) in 
relation to BBV testing  
 The importance of effective relationships between TSPs and injectors  
 The appropriateness of the language used in the guidelines  
 The use of the terms “pre- and post-test discussion” rather than “pre- and post-
test counselling” to reduce confusion, more accurately reflect the focus of 
these sessions, and defuse any concern or anxiety as to what might be expected 
from “counselling”  
 If new guidelines are suggested, TSPs will need to be made aware of them and 
receive some support in their implementation. A further strategy would be to 
inform injectors about what they could expect when they request BBV testing. 
In conclusion, we believe that a test event is a not only a medical but also a 
psychosocial intervention to prevent risk behaviour. Both injectors and TSPs need to 
have the expectation that a test event is an opportunity for them to discuss why the 
October, 2001 National Drug Research Institute 
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injector could be infected and how further risk to the individual and the community 
could be avoided.  
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PROPOSED GUIDELINES FOR BBV TESTING WITH INJECTORS 
Pre-test discussion should always be in person no matter what the reason for the test. Pre-test discussion aims to provide the individual with the 
information, ability and opportunity to give informed consent to the BBV test. 
At first test At subsequent tests 
Essential1 Essential1 Negotiable2 
 Provide clinical information about the virus  Assess risk 
Include exemplars for assessing risk 
 Provide clinical information about the virus 
 Assess risk 
Include exemplars for assessing risk 
 Provide information about the test 
and the possible consequences and 
benefits of testing including 
confidentiality and notifiability 
 Identify support available to the patient. 
 Provide information about the test and the 
possible consequences and benefits of testing 
including confidentiality and notifiability 
 Discuss whether the patient is ready 
and able to give informed consent. 
Gain informed consent  
 Provide additional information about the virus  
Format and language of information should be 
appropriate to the person’s literacy and language 
skills. 
 Provide additional information about the virus  
Format and language of information should be 
appropriate to the person’s literacy and language 
skills.  
 Arrange the post test discussion  
Provide option to bring a support person 
when receiving results. 
 
 Discuss whether the patient is ready and able to 
give informed consent. Gain informed consent 
  
 Identify support available to the patient.   
 Arrange the post-test discussion 
Provide option to bring a support person when 
receiving results. 
  
1Essential; these guidelines should be included in every pre- and post-test discussion regardless of the person's testing history, relationship with TSP, knowledge of blood borne viruses or current situation. 
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2Negotiable: these guidelines could be negotiated between the person being tested and the test service provider based on the person's testing history, relationship with TSP, knowledge of blood borne viruses or current 
situation. 
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Post-test discussion should always be in person no matter what the reason for the test or whether the result is positive or negative. The purpose 
of post-test discussion is to ensure the individual understands the meaning and implications of the test result and is provided with support, 
information and referral as appropriate.  




 Facilitate discussion which provides harm 
reduction information to prevent exposure to the 
virus. Assist the person to develop skills in 
remaining infection free.  
Discussion should be based on the pre-test risk 
assessment.  
 Provide immediate counselling and 
assess other sources of support 
Incorporate positive result giving into two 
stages as appropriate. It is recommended 
that this guideline be addressed at the 1st 
appointment.  
 Refer to external sources of support 
such as longer-term counselling or a 
local Hepatitis C Council  
Incorporate positive result giving into two 
stages as appropriate. It is recommended 
that this guideline be covered at the 1st 
and/or 2nd appointment  
 • Provide support and information to 
prevent transmission  
Incorporate positive result giving into two 
stages as appropriate. It is recommended 




Discussions in this situation should be couched appropriately according to the individual, their level of risk and the likelihood of a positive or negative result. 
 
National Drug Research Institute October, 2001 

Talking about testing 9 
INTRODUCTION  
BACKGROUND TO THE RESEARCH 
Australian injecting drug users are commonly tested for blood borne viruses (BBVs) 
(hepatitis C, hepatitis B and HIV/AIDS). Thus in the 1994 Australian Study of HIV 
and Injecting Drug Use (ASHIDU), 79% of 872 injectors had been tested for hepatitis 
C, 81% had been tested for hepatitis B and 91% had been tested for HIV/AIDS. Even 
though these results were influenced by age and treatment status, more than half of 
younger injectors who had never been in treatment and had the lowest testing rates, 
had been tested for all three viruses (Loxley, Carruthers & Bevan, 1995).  
There are an estimated 200 000 hepatitis C infections in Australia; more than 125 000 
people have been notified with hepatitis C since antibody testing became available in 
1990 and there are now around 18 000 – 20 000 notifications a year (NCHECR, 1999). 
Eighty percent of infections are considered to be as a result of injecting drugs (Lowe 
& Cotton, 1999).  
Hepatitis B was first identified as a virus in 1965, long before HIV/AIDS and hepatitis 
C, but, perhaps because of this, seems never to have assumed the same significance in 
the mind of injectors, the community and, possibly, health professionals. In Australia 
there are 150 000 – 180 000 infected individuals with an estimated 1 200 deaths per 
annum (Batey & Bollipo, 1996). Hepatitis B is efficiently transmitted by blood, 
vertical transmission and sexual contact, and people who inject drugs are at high risk 
of infection. While it has been overshadowed by the hepatitis C epidemic, this does 
not decrease its importance as a major cause of severe liver disease, morbidity and 
mortality (Batey & Bollipo, 1996). In Australia, the National Health and Medical 
Research Council (NHMRC)’s recommendation of universal vaccination to prevent 
hepatitis B has been adopted, but the uptake of vaccination by high-risk populations 
such as people who inject drugs is far from complete.  
A considerable literature exists in relation to human factors involved in testing for 
HIV, but there appears to be little or no literature related to human factors in testing 
for hepatitis C and B, or vaccinating against hepatitis B. In terms of testing for 
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HIV/AIDS, Beardsell (1994) pointed out that while national HIV/AIDS test policies 
appeared to be based on the assumption that there was a correlation between 
HIV/AIDS testing/counselling and behaviour change, that assumption was simplistic 
and failed to take account of the complexity of sexual and drug using behaviours, and 
the range of motivations for participation in testing. She cited a review of twelve 
studies of testing and injecting drug use which found that behaviour changes were not 
linked to knowledge of HIV/AIDS status. 
Phillips and Coates (1995) asserted that research should investigate not only the initial 
decision to be tested, but also follow-through. Lindan et al. (1994) investigated 
HIV/AIDS testing among alcoholics and drug users and concluded that there was 
substantial misunderstanding or misreporting of test results, maintaining that this 
"underscores the need to improve testing and counselling procedures in this group" (p. 
1155).  
These studies suggest that being tested is not necessarily a valuable or useful 
experience for individuals. Research over some years at the National Drug Research 
Institute (NDRI)1 into the relationship between injecting drug use and BBVs has led to 
some similar conclusions. The thrust of our concern is that failure to take account of 
the complex human factors involved in testing can either deter individuals from 
presenting for testing, or render testing ineffectual for both the those tested and her/his 
community. Particular difficulties we have identified include motivations for being 
tested that include the desire to maintain current behaviour patterns rather than reduce 
risk; intimidatory testing processes that deter some (particularly young) injectors from 
presenting for testing or from collecting test results; failures to understand the 
meaning of test result which may result from inadequate pre- and post-test 
counselling; over-testing; and uncertainty about serostatus and hepatitis B vaccination 
process or status (Loxley, 1991, Loxley, 1998, Loxley et al., 1995).    
                                                 
1 Formerly the National Centre for Research into the Prevention of Drug Abuse 
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TESTING INJECTORS FOR  BBVS – RESEARCH IN PERTH  
In 1997 the NHMRC funded NDRI to conduct an investigation of some of the human 
issues involved in testing injectors for BBVs and vaccinating them against hepatitis B. 
Issues investigated included the decision to be tested or to test, the test process and test 
outcomes. Two hundred injectors, stratified for age and experience in drug treatment, 
were recruited in Perth and interviewed in person, and 39 test service providers (TSPs) 
from every State and Territory were recruited and interviewed by phone. Data in both 
sets were qualitative and quantitative. The study has been reported by Loxley, 
Davidson, Heale and Sullivan (1999). 
There were 103 male and 97 female injector respondents. Their ages ranged from 14 
to 47 years with a mean of 26.1 and a median of 24 years. The majority were not 
married or living with sexual partners, and nine out of ten were heterosexual. Five 
were Indigenous Australians. Most had used alcohol, cannabis, hallucinogens, 
amphetamines, heroin, ecstasy and benzodiazepines at least once, and just under half 
had used methadone at least once. Almost all of the respondents who had used heroin 
or amphetamines reported injecting these drugs at some time. Of the 182 respondents 
who had ever used heroin, 96% reported injecting within the last year and 67% within 
the last month. The main drug injected by over three quarters of respondents was 
heroin.  
Around 70% of respondents had been tested for at least one BBV one or more times 
and most of these had been tested for all three. Much of the testing had been 
undertaken in batteries of all three tests. The average (median) number of tests 
received was as follows:  
 Hepatitis C   5.6 (4) 
 Hepatitis B   5.8 (3)  
 HIV/AIDS    6.4 (4)  
Approximately 7% had received more than 10 tests for each virus. 
Twenty four percent of respondents reported that they had been vaccinated against 
hepatitis B: almost 60% believed that they had not been vaccinated, 9% reported that 
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they were hepatitis B antibody positive, and 8% did not know whether or not they had 
been vaccinated. 
Thirty nine TSPs were interviewed throughout Australia: half from rural and half from 
metropolitan areas. One third were community GPs and one third were recruited from 
sexual health clinics. The remainder worked in drug treatment centres, hospitals, 
prison medical services, gay and lesbian medical services, community health services, 
youth health services and/or other agencies including contact tracers. On average, 
agencies saw 706 clients per month. Test service providers reported that they ordered 
an average of 40 hepatitis C antibody tests, 51 hepatitis B antibody tests and 52 
HIV/AIDS tests a month. They also carried out an average of 19 hepatitis B 
vaccinations a month. 
While almost all the injectors were aware of the risks posed by BBVs, there were three 
major reasons for being tested:  
 the respondent had been exposed to risk in some way  
 the test was recommended or required  
 the respondent was concerned about the possibility of infecting others.  
A further category, only applicable to hepatitis B testing, was that the respondent had 
experienced signs or symptoms of illness. 
Respondents’ reasons for not being tested included the belief that they were not at risk, 
failure to ‘get around to it’, and/or being scared or nervous about test outcomes. Some 
respondents had never heard of a hepatitis B test.  
Test service providers reported that their injector clients were offered testing if they 
had disclosed past or current injecting drug use during history taking, and/or if they 
self-referred for testing. A few said they tested injectors routinely and some said 
clients were tested if there were symptoms present, an abnormal liver function test was 
detected, or as part of an STD screen. Over a third of TSP informants said they would 
re-test a client every time a test was requested. 
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Testing and Vaccination: Experiences of Injector Respondents  
One hundred and fifty testing events were described by injector respondents. Most of 
these were descriptions of batteries of all three tests and only 17% described a first test 
experience. Most tests had been instigated by the injector and for many the experience 
was routine. Three quarters claimed to have received no pre-test counselling although 
some said that this was because they did not want or need it. However, some 
misunderstood the question “were you offered any pre-test counselling?” apparently 
believing that this asked whether they were referred to another person or agency for 
counselling prior to being tested. Whether or not respondents received pre-test 
counselling was related to the nature of the service provider who ordered the test, such 
that GPs and hospitals were reported as being less likely to have provided counselling 
than medical, sexual health and drug treatment clinics. 
Respondents reported that they had received their test result in a personal interview 
with their TSP on almost three quarters of occasions. However, on around one in ten 
occasions they had received them by telephone. Some respondents had not collected 
their results: most of these because they believed that they would be informed if their 
results were positive. They reported that no post-test counselling was given on 81% of 
described test occasions, and that whether post-test counselling occurred related to the 
test result. Clients who received post-test counselling were more likely to be 
seropositive for at least one test than clients who were not counselled. It should, 
however, be noted that post-test counselling was reported to have been received on 
only approximately 30% of test events resulting in at least one positive result, as 
shown in Figure 1:  
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Positive (n = 56) Negative (n = 90)
Test result
Counselled Not counselled 
 
Figure 1: Test outcome by post-test counselling: most recent testing occasion 
(n = 146) (Loxley et al., 1999) 
Injectors tended to subscribe to the view that the major role of post-test counselling 
was to follow up positive results, and many of those who described post-test 
counselling reported it in terms of medical advice given if they were hepatitis C 
positive. Only four respondents described post-test counselling which contained 
preventative advice. Respondents reported only nine test occasions which resulted in 
referral to other medical or community agencies, with most of these referrals being to 
specialist medical services. Most said they did not know at the time about local 
community-based support agencies. 
Injector respondents reported that on almost 40% of occasions they experienced some 
anxiety particularly while waiting for results. While most of those whose results were 
negative said that they were pleased, relieved, or not surprised; those who received 
positive test results were almost equally divided between being upset/ angry/ 
concerned, not surprised or focused on their state of illness or health. 
Those who had been tested at least once were asked if they had changed their 
behaviour in any way subsequent to their last test. The majority of respondents, 
regardless of the test outcome, had not changed their behaviour, with the most 
common reason for this that they were “already safe”. 
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Almost half said that they knew little or nothing about hepatitis B vaccination. Many 
of those that had not been vaccinated had never heard of it or did not realise that such 
a vaccine was available and/or no-one had ever suggested they should be vaccinated or 
offered them the opportunity. The most common reason given for being vaccinated 
was that it was suggested by a doctor or clinic staff. 
Testing and Vaccination: Views of Test Service Providers 
All TSP informants said that pre- and post-test counselling was provided for a BBV 
test. The majority reported using pre-test counselling to assess the client’s risk, discuss 
transmission and prevention, give information about the viruses, tests and window 
periods, and establish what clients would do if they received a positive result. The 
majority also reported that they always gave all BBV results face to face but a few 
said that they were less stringent with hepatitis C and B than with HIV/AIDS results, 
and were prepared to give these results over the phone. Test service providers’ main 
explanation for injectors’ failure to collect results was that the population was 
transient and mobile. 
Almost all TSP informants said they used post-test counselling after negative results to 
discuss prevention. Most said they used post-test counselling for positive results to 
suggest follow-up and monitoring, including further testing and referral to specialists, 
and to discuss transmission and prevention issues. One in three mentioned referring 
patients to alcohol and drug services, sexual health clinics, and support services. 
They described observing a wide range of emotional states, but predominantly anxiety, 
in their BBV tested clients. Most said they dealt with these reactions with counselling 
but one in three said they provided more information and some referred these clients. 
All TSP informants believed that injectors needed to be advised to be vaccinated. Half 
said that vaccination came about mainly as a result of their recommendation. Some 
thought that hepatitis B vaccination needed to be promoted more. 
Implications of the Data 
The study showed that the process of testing, as reported by the injectors, was, in 
many cases, far from satisfactory. Test service providers ordered many tests each 
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month, and tested injectors had typically had more than one test, but in many cases 
injectors were not motivated to make behaviour changes as an outcome of testing, 
with some being more concerned to use testing as a way of proving themselves 
uninfected. Moreover, many TSPs were willing to test whenever they were requested 
to do so without questioning whether there was any behavioural outcome. All of this 
suggests that the only purpose served by much of the testing was the diagnosis of 
infection and the implementation of appropriate medical interventions. This falls well 
short of what is intended for hepatitis C testing according to the NHMRC Guidelines 
for TSPs when testing for hepatitis C (NHMRC, 1997). These provide standards for 
pre- and post-test counselling which suggest that the outcomes of counselling should 
be the provision of psychosocial support, prevention of the transmission of hepatitis C 
and the optimisation of treatment outcomes. The data suggested that, in the main, only 
the last of these outcomes was being met. Much of the counselling suggested in the 
Guidelines was not occurring, and post-test counselling was rarely used except as a 
medical intervention after positive results. While a range of emotional experiences 
related to being tested was described by both clients and TSPs, very few clients said 
they were referred to local support agencies such as the Hepatitis C Council. In 
general, the testing process, as described by injector respondents, did not actively 
encourage seronegative injectors to initiate behavioural change, nor seropositive 
injectors to regard their normal injecting behaviour as behaviour which might transmit 
infection to others. 
Reported low levels of vaccination were also a concern. Most of the respondents in 
this study had been tested for hepatitis B because they were injectors, but few had 
been vaccinated, even though many of them had received negative results.  
THE PRESENT STUDY 
BBV testing is a common way in which injectors make contact with health and 
medical services. It therefore presents an ideal opportunity for health promotion and 
harm minimisation interventions. This is in keeping with the tradition of testing for 
HIV/AIDS which, from the earliest stages of the epidemic, was seen as an opportunity 
to prevent as well as diagnose disease: pre-test counselling was designed to inform 
about the test and obtain informed consent, and post-test counselling was understood 
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as a ‘key element in the medical and psychological management of infection 
…[and]… for people who returned negative tests, to reinforce their continuation in a 
negative condition” (DCSH, 1989, p. 5).  
The NHMRC Hepatitis C Testing Guidelines recognise the potential of testing as a 
brief intervention. However, the first study demonstrated that more information was 
needed from doctors, injectors and other key informants about limitations and 
difficulties with Guidelines such as these. The present study is an examination of 
clinical and practical difficulties with the NHMRC Guidelines. The report concludes 
with proposals for modified guidelines for pre- and post-test discussions when testing 
injectors for blood borne viruses, and specific recommendations to maximise the 
efficacy of the testing process as an intervention which can prevent and limit the 
spread of blood borne viruses among injecting drug users in Australia. 
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METHOD  
AIMS AND OBJECTIVES  
This project aimed to deepen knowledge about the process of testing injectors for 
hepatitis C and other blood borne viral infections and to develop concrete 
recommendations for changes to the testing process.  
Specific objectives were: 
 To use the data gathered in the first testing study (Loxley, Davidson, Heale & 
Sullivan, 1999) as a basis for a more in depth investigation of the NHMRC 
Hepatitis C Testing Guidelines.  
 To investigate clinical and practical difficulties experienced by tested injectors, 
and TSPs with these Guidelines 
 To recommend ways to improve the structure, content and implementation of BBV 
testing guidelines in order to increase the efficacy of BBV testing for Australian 
injectors.  
 To make recommendations available to relevant bodies through appropriate 
publications and presentations.  
CONSULTANTS 
The project was informed at every stage by consultants drawn from a range of relevant 
organisations (Appendix I). Some of these consultants met with the Project Officer as 
a Steering Group five times in the 6 month period of project design and 
implementation and again in finalising the conclusions of the study, while others were 
consulted independently. Consultants were asked to assist the research by:  
 Identifying the specific issues to be covered in the study 
 Providing initial advice in relation to methodological issues 
 Having input into establishing methodology and recruitment strategies 
 Assisting with the development of questions and themes for focus groups and/or 
interviews  
 Providing feedback on the analysis of relevant data 
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 Providing input into recommendations  
 Commenting on the report  
Donations were made to the Western Australian Substance Users Association 
(WASUA) and the Hepatitis C Council of WA (HCCWA) in recognition of their 
significant contribution as consultants to the study. 
RECRUITMENT  
It was intended to recruit approximately 20 injectors, and 20 health professionals 
including test service providers (TSPs) and key informants (KIs) to the study. The 
following were start points for recruitment:  
 Nominations from consultants and snowballing.  
 The HCCWA and the WASUA promoted interviews and focus groups to their 
members.  
 Youth organisations (Trinity Youth Options, the Perth Inner City Youth Service 
and the Hills Youth Centre) promoted interviews to their client group.  
 Newsletter of the HCCWA 
 Information to delegates at the 1999 Annual Conference of the Australasian 
Society for HIV Medicine 
 The HCCWA Shared Care project 
Inclusion criteria for respondents were as follows: 
Injectors 
 Tested for hepatitis C in the past 2 years 
 Never tested positive for HIV (people who have tested positive for HIV were not 
interviewed as part of the study as the post test counselling they may have received 
at this time may have contraindicated counselling for other blood borne viruses.) 
 Aged 18 and above.  
Health Professionals  
 GPs with an interest in BBV (TSPs) 
 GPs who do not currently practice much in the area of BBVs (TSPs) 
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 Representatives from organisations who provide BBV testing (TSPs) 
 Representatives of agencies who have a professional interest in BBV testing (KIs)  
DATA COLLECTION 
Overview  
The data collection methodology was primarily qualitative, using a number of 
different techniques (interviews, focus groups, and consultations) to develop a total 
data set upon which conclusions and recommendations were based. The approach was 
loosely based on some elements of Grounded Theory (Strauss & Corbin, 1990) in that 
it did not aim to prove or disprove a pre-existing theory, but to allow relevant theories 
to emerge from the studied phenomenon. It was also collaborative, with researchers, 
practitioners and representatives of the population of interest working together in the 
belief that valuable knowledge about ways to overcome the barriers to effective pre- 
and post-test counselling would be held by all those who participated in the research. 
The analysis was flexible and reflective, with each stage of the research process 
incorporating opportunities for analysis and consideration of where data collection 
should proceed in subsequent stages.  
Interview Guides  
The major issues to be considered by the research were drawn from questions posed at 
the conclusion of the first study (Loxley et al., 1999).  
 How appropriate are the current Guidelines for either hepatitis C or HIV/AIDS 
testing, when most injectors undertake these tests in batteries? 
 How relevant are the Guidelines to injectors who are regularly tested? 
 Under what circumstances should the Guidelines be followed closely? 
 Under what circumstances are the Guidelines not appropriate? 
 What should the role of testing be in promoting change towards safer behaviour? 
How can that best be facilitated? 
 How practical is it to expect TSPs to implement the Guidelines given the cost 
recovery structures of most practices? 
October, 2001  National Drug Research Institute 
Talking about testing 21 
 What are the barriers to the vaccination of injectors against hepatitis B? How can 
these best be overcome? 
The specific issues raised in the Interview Guides were as follows2:  
Injectors  
 Demographics  
 Drug use  
 Serostatus 
 Testing experience 
 Reaction to NHMRC Hepatitis C Testing Guidelines  
 Comments on pre- and post-test  counselling  
 Comments on hepatitis B vaccination  
Health Professionals  
 Demographics 
 BBV testing scenarios (for TSPs only) 
 BBV testing amongst relevant client group (for KIs only) 
 Reaction to the NHMRC Hepatitis C Testing Guidelines 
 Implementing the NHMRC Hepatitis C Testing Guidelines  
 Comments on hepatitis B vaccination  
Focus Group Guide  
 Introduction to the study 
 Introduction to the NHMRC Hepatitis C Testing Guidelines 
 Implementing pre- and post-test  counselling  
 Alternative models for pre- and post-test  counselling 
                                                 
2 Copies of the Guides can be seen in Appendix II  
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Stages of Preparation, Data Collection and Analysis   
The phases of the study are depicted in Figure 1. It will be seen that the process was 
iterative, with consultation and communication with consultants occurring at every 
stage.  
Data Collection Procedures 
Interviews with injectors and health professionals were tape recorded and transcribed. 
The majority of interviews with injectors took place at cafes in inner city Perth, with 
some interviews being conducted at youth organisations. Interviews with injectors 
were conducted between June and August 2000. Injector respondents were paid $30 
for participation in interviews. 
The majority of health professionals were interviewed at their workplace. Interviews 
with health professionals were conducted between July and September 2000. Health 
professionals were not paid for participating in the study.  
The focus group for health professionals took place at the Annual Conference of the 
Australian Professional Society on Alcohol and Other Drugs (APSAD) in November 
2000. The focus group for injectors and user representatives was held at NDRI in 
April 2001. Injectors were paid $30 to take part. The focus groups lasted 
approximately one and a half hours each. It was not necessary to tape record the focus 
groups. 
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Ethical Issues: Privacy and Confidentiality 
This study was approved by the Curtin University Human Research Ethics Committee. 
No identifying information about respondents was collected and results are presented 
anonymously. All research questionnaires, audio tapes and any other recordings of 
focus groups or interviews were kept in a locked cabinet. Clerical staff responsible for 
transcribing interview tapes signed a confidentiality agreement at the commencement 
of their contract.  
Respondents were informed of the privacy and confidentiality issues at the 
commencement of interviews and/or focus groups by way of a Respondent 
Information Sheet. Participants in the focus groups were reminded by the convenor of 
the group of the confidential nature of the study and asked not to breach the 
confidentiality of other focus group participants. 
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RESULTS 
PHASE 1 DEVELOPMENT OF INSTRUMENTATION AND DATA 
COLLECTION  
The Interview guides (Appendix II) were developed in consultation with the 
consultants. There were two major rounds of data collection in this phase with 
injectors and health professionals. 
In-depth Interviews with Injectors  
Demographics 
There were 19 respondents, almost equally divided between males and females. Half 
were aged 31 or over, and three were under 20. Almost all lived in the Perth 
metropolitan area. There were three homo- or bi-sexual respondents. No respondent 
identified as an Indigenous Australian. Most of the sample described themselves as 
Australian, with two coming from the UK and four from other countries. 
Drug use and drug treatment: access to services  
Fourteen respondents were primary heroin injectors; three were primary amphetamine 
injectors and two were polydrug injectors (heroin, amphetamines, temazepam). Half 
had first injected between the ages of 16 and 20, and almost half had been injecting for 
11+ years. Half of the sample were in treatment at the time of interview. Between 
them, respondents had experienced 48 different treatment modalities at some time 
(they could also have experienced more than one episode of each modality).  
The majority of respondents had seen a GP at least six times (range 12 – 50) in the 
previous 12 months. Almost half (47%) had a single regular GP, 16% saw 2 – 3 GPs 
on a regular basis, and the remainder did not have a regular GP. Some respondents 
reported that they had a good relationship with their GP, describing them as role 
models or friends but some appeared to have a more mechanistic view of 
appointments with their GP, stating that the purpose of visits was to “fix” particular 
problems. Some suggested that their GP did not care, or did not have time for them.  
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Respondents were asked about the frequency of their visits to WASUA, the Western 
Australian Substance Users Association. Based in inner city Perth, WASUA provides 
needle and syringe exchange, medical services, BBV testing and HBV vaccination, 
information, support and treatment referral for injectors. Half had visited WASUA at 
least once a week; six visited once a month or less and three had never been to 
WASUA. Almost all had accessed the needle exchange; eight had been in contact with 
the nurse in relation to BBV testing and/or HBV vaccination; five had sought 
information and two had been referred to treatment.  
Blood Borne Virus status and testing 
All respondents had been tested at least once within the last two years, as this was one 
of the inclusion criteria for the study. The average number of times respondents had 
been tested was 16.1 (range 1 – 100+). When the 100+ response was removed the 
average was 9.6 times. Of those tested regularly, the most commonly nominated 
interval for testing/retesting was 6 months (range from 2 – 3 weekly to annually).  
Six respondents (31.5%) reported that they were hepatitis C positive; 12 reported that 
they were negative, and one was unsure. No respondent reported hepatitis B infection: 
10 reported that they were hepatitis B negative, and five that they had had previous 
exposure to the virus, but had now cleared it. Four reported that they did not know or 
were unsure of their HBV status. Seven reported that they had been vaccinated; seven 
that they had not; three had not completed a vaccination course, and two did not know 
or were unsure of whether they had been vaccinated.  
Comments about Blood Borne Virus testing  
This section introduced the qualitative section of the interview. Respondents were 
guided through a series of discussion points with open-ended questions.  
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The majority of respondents did not understand the terms pre-test counselling3/post-
test counselling, or know what might be involved. Some confused them with 
therapeutic counselling. A few, however, had a good understanding:  
I understand pre-test counselling to be whoever is testing you, to go through 
what the outcomes may be. I would expect someone to ask me what would my 
reaction be to the outcomes, being negative or positive. I guess reassurance for 
pre-testing and I would expect the same thing from post-testing as well, like 
support. 
Most respondents were tested more than once a year. A number of incidents and 
events occasioned testing: wanting to be tested regularly; going into treatment or other 
medical intervention; engaging in risky behaviour and/or being anxious about their 
infection status. Most did not believe that regular testing offered protection against 
unsafe behaviour, but saw it more in terms of ‘peace of mind’ and ‘protection for 
others’. A minority believed that testing offered an opportunity to learn about 
transmission avoidance, or motivated those with negative tests to be more careful in 
the future:  
If you know you're clean you want to keep it that way, whereas if you don't, 
you're sort of like, well you know, you don't really sort of care. … Now I 
know that [I’m negative] I'm never ever going to do the same thing again after 
that test. ‘Cause I'm clean and I want to keep it that way. 
Respondents were asked whether they felt they needed pre- and post-test counselling 
at each test. This question was asked prior to an explanation of how such counselling 
is described in the Guidelines, and was asked again after that. The majority of 
respondents did not believe they needed full pre- and post-test counselling on each 
occasion. Many believed that the extent of counselling needed would depend on the 
individual and the circumstances at the time:  
Not every time, it depends on how I'm feeling. Sometimes I have been clean 
for a couple of months and feel really good within myself, but sometimes I 
feel like everything is really full on and chaotic. Sometimes I say to my 
                                                 
3 It is appreciated that the terms “pre-test counselling” and “post-test counselling” may not be the most 
appropriate terms for these interactions. This issue is raised more fully in the Discussion. The terms are 
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doctor, look if I am diagnosed with HIV I am going to kill myself. … So 
therefore sometimes I do think I need to, to prepare myself. 
In terms of perceptions of the TSPs’ role in the decision to test and the provision of 
risk reduction support, most believed that the decision to be tested should rest with the 
patient rather than the doctor, but there was a degree of support for compulsory testing 
under some circumstances or for some people. Most believed that TSPs could help or 
support in risk reduction. However, just over half cited negative experiences with 
medical staff, particularly with GPs, which were mainly related to the perception that 
doctors did not like drug users. On the other hand, a large minority liked and trusted 
their GP. Some had experienced alcohol and drug doctors (eg at treatment agencies) as 
more sympathetic and understanding than GPs.  
The NHMRC Guidelines for Pre- and post-test Counselling 
Figures 3 and 4 show the NHMRC Guidelines for pre-test counselling and post-test 
counselling for hepatitis C testing.  
According to the guidelines, pre-test counselling should: 
1.1.  Assess risk 
1.2  Provide clinical information about the virus 
1.3  Enable the patient to decide whether they should be tested 
1.4  Provide information about the test and the possible consequences of testing, 
including confidentiality and notifiability 
1.5  Provide information on testing benefits 
1.6  Establish the ability to give informed consent 
1.7  Identify support available to the patient. 
1.8  Provide a written summary of the information covered in the pre test 
counselling preferably in the testee’s native language 
1.9  Make arrangements for a post test counselling appointment 
Figure 3: NHMRC Guidelines for Pre-test counselling  
                                                                                                                                            
used here because they were the terms used in the research.   
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Post test counselling should: 
2.1  Always be in person no matter what the reason for the test or whether the result 
is positive or negative 
2.2  Ensure that the patient understands the meaning and implications of the test 
result 
2.3  Ensure that appropriate referrals and psychosocial interventions occur if 
required 
If patient is negative: 
3.1  Counselling should provide information to prevent exposure to the virus  
3.2  The individual should be assisted to adopt relevant skills to remain infection 
free 
If patient is positive: 
4.1.  Immediate counselling should be provided 
4.2  Support and information to prevent transmission to others should be provided 
4.3  The extent of personal support should be assessed 
4.4  Referral to external sources of support such as longer-term counselling or a 
local Hepatitis C Council should occur 
Figure 4: NHMRC Guidelines for Post-test counselling 
In this section respondents were asked whether they were aware that Guidelines 
existed and then asked to comment on each. Almost no-one had heard about the 
Guidelines. For each Guideline that follows we asked: Did your GP/TSP do this at 
your last test? If no, why not? If yes, how did you feel about it? Not all Guidelines 
were discussed by respondents, and in some cases Guidelines were amalgamated in 
discussion. Responses are categorised according to the Guideline number(s).  
1.1 Pre-test: Assess risk 
The majority said this had happened but few details were given. Where they were, the 
assessment appeared to have mainly related to a discussion of sharing needles with 
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little detailed assessment of the specific behaviours which put the individual at risk. 
Where risk was not assessed, the respondent said that the doctor “knew” they were at 
risk (because they injected). In some cases, risk had previously been 
discussed/assessed.  
1.2  Pre-test: Provide clinical information about the virus 
Most respondents did not receive clinical information at their last test and around half 
thought it would be a good idea. They stressed, however, that the information should 
be new and not repetitive and that injectors should have the option of saying “I know 
that – let’s move on”.  
1.3 Pre-test: Enable the patient to decide whether they should be tested. 
1.6 Establish the ability to give informed consent.  
These two Guidelines related to the same issue: who made the decision for the test? 
Respondents were almost equally divided between those who asked for the test, those 
who felt they had no choice, and those who felt that there was some interaction with 
the TSP relating to consent. There were also strongly held views that a) doctors should 
not refuse to test anyone who asked for it or b) that some injectors should be 
compulsorily tested:  
They shouldn't ask you, do you want to be tested. If someone asked to be 
tested, they asked to be tested, whether or not they've got a chance of catching 
it or not. It's their own peace of mind. The doctor shouldn't be able to say, no 
I'm sorry I don't want to give you a blood test because you're in the no risk 
category, because that's just plain stupidity. The doctor’s not there twenty four 
hours a day, doesn't see … I mean especially blood borne, you know, you can 
sit there and touch someone who's got blood and stuff like that, you don't 
know. The doctor shouldn't tell you. If you want to have a test, you should go 
and have a test. 
Well I reckon if that you are an IV user, you should just get tested. I think it is 
good that GPs automatically seem to do it, rather than you deciding yourself, 
because quite often you're not in a state to decide yourself. 
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One respondent thought that a formal consent process, whatever the motivation for the 
test, was a good idea:  
Yes, I can see the benefits of having something like that. The contract at the 
beginning, 'do you have any questions before we proceed to get your blood 
taken?’ I think that would be a good idea actually. 
1.4 Pre-test: Provide information about the test and the possible consequences 
of testing, including confidentiality and notifiability 
About half of the respondents were not told about the notifiability of positive results, 
and a similar number thought that they should be.  
They've got nothing to hide, they should tell everyone. That's like if they don't 
tell them, it's like they got something to hide. I'm hiding this from you, that 
you're going to be on this list, you know? 
Some concern was expressed, however, about the possibility that those who were 
notified as hepatitis C positive would have their names placed on the list of registered 
addicts held by the Heath Department. 
But you don't want to scare people away either, because it does in a way. Like 
I think, 'oh my god, what if I am positive, I would be on the list', but it should 
all still be free choice and nothing should be hidden, to come as a surprise 
later. 
The majority had been informed about confidentiality at their last test and believed 
that this was appropriate.  
1.5 Pre-Test: Provide information on testing benefits 
Almost no-one was told about the benefits and consequences of testing (eg in terms of 
insurance, discrimination etc) apart from the clinical aspects. Most did not see this as 
vital and some thought it might deter some injectors from being tested. 
1.7 Pre-test: Identify support available to the patient. 
This question asked whether TSPs established prior to the test that the patient had 
access to support in the event of a positive result. Respondents were almost equally 
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divided between those who said this had, and those who said it had not been 
established. Some felt that their TSP did not need to ask because he/she knew them 
well enough to know what levels of support they had. Almost all believed that 
identifying support was important. Some of those whose TSP did not ask about 
support, felt that this was because TSPs did not care, did not understand or had other 
priorities for the patient (eg drug treatment).  
 I feel if I hadn't been a drug user, and it was some other patient, he would've 
dealt with it completely differently … would've probably been a bit more 
compassionate about what the result would've been and my effect on the 
result. 
1.8 Pre-test: Provide a written summary of the information covered in the 
pre-test counselling preferably in the client’s native language 
About half were given access to some written material, usually pamphlets, at their last 
test. These did not appear to have been specific to the doctor or sometimes even the 
virus for which the test was ordered. No-one was given a written summary of all the 
information conveyed in the pre-test counselling. Not everyone thought written 
material was a good idea: some did not like reading, and some thought pamphlets were 
a waste of time. Some were concerned in case written material was used as an 
alternative to face to face discussion.  
3.1 Post-test for a negative result: Counselling should provide information to 
prevent exposure to the virus.  
3.2 The individual should be assisted to adopt relevant skills to remain 
infection free 
There was strong support for the notion that TSPs could use post-test counselling to 
help them to remain free of BBVs. Comments indicated that harm reduction was 
complex and that injectors could always use more help. Testing was seen as a good 
opportunity to do this because patients were motivated to avoid risk. Some also 
realised that previously unknown risk behaviour might be exposed and then discussed:  
Yes, because a lot of things I didn't even realise. Like seriously, one of the 
things that I realised only a short while ago … A little while before that, if 
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someone has a dirty fit and I have a clean one and we are sharing the same 
spoon, that I could still get infected. I had no idea. I wish I had found that out 
a lot earlier you know. I am sure there are a lot of people like me. 
However, there was a strong sense that responsibility for ensuring that prevention 
counselling was useful rested with the TSP. A number commented on GPs apparent 
lack of time for long consultations, and were concerned that many TSPs would not 
have enough time for these discussions.  
4.1 Post-test for a positive result: Immediate counselling should be provided 
It is unclear whether those respondents whose last test was positive had received 
immediate support. Almost all thought that a positive diagnosis was sufficiently 
serious for this to be an important Guideline. One described how devastating a 
positive result could be:  
No-one was aware, my friend, you know girlfriend, thought I was gonna die, I 
thought I was gonna die, my mum thought I was gonna die, we all sort of 
yeah, thought this was it. 
4.2 Post-test for a positive result: Support and information to prevent 
transmission to others should be provided 
Some respondents who had received positive results had had discussions with their 
TSP about blood awareness, tattooing etc. Most thought that it was important although 
perhaps not at the first post-test appointment:  
I think with the first one [appointment] I would try and just make sure that the 
patient was okay, emotionally and mentally, like okay to be actually leaving 
that building and so they are not going to go out and maybe fuck someone 
because they have got HIV and they are really angry or Hepatitis C and they 
are really angry, because that happens. It should be the doctor’s main concern 
that the person is leaving in a really safe environment and then the follow-up 
about transmission. 
Some thought this could be better done through referral to organisations like the 
Hepatitis C Council or User Group because of the need for support from like others: 
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Sitting down with all of those other people, you hear from them and you don't 
feel alone. 
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4.3 Post-test for a positive result: The extent of personal support should be 
assessed 
Three quarters of those who had received positive results said that there was no 
discussion with their TSP about immediate support. All respondents thought that it 
was important:  
Yes, I think that should be asked. You know, leaving the office and going 
home to somebody or having somebody close by, and that kind of thing, you 
should have somebody there for you. I think it is a doctor or whoever is giving 
the post-test counselling afterwards that should check with that person if they 
have got support. 
4.4 Post-test for a positive result: Referral to external sources of support such 
as longer-term counselling or a local Hepatitis C Council should occur 
A majority of respondents thought that referral to support agencies was a good idea, 
although many stressed that these should be optional. A few had had such referrals and 
found them useful:  
I didn't, you know, do anything straight away because I was so shocked. But, 
yeah, it was helpful. I rang a few of the numbers and stuff and it was alright. 
Implementing the NHMRC Guidelines for Pre- and post-test Counselling  
Respondents were almost equally divided between those who thought that the 
Guidelines for pre- and post-test counselling should be administered in full on every 
occasion with every injector, and those who believed that injectors who were tested 
regularly did not need all the Guidelines on every test occasion. Most respondents 
thought that they, personally, would not need full counselling on each occasion, but 
that it depended on the individual, their relationship with their doctor, the frequency of 
testing and the rate of change of information. Most thought that they would be most in 
need of pre- and post-test counselling at their first test, if they were positive or likely 
to be positive and/or if they were worried or anxious. There was a strong feeling that 
at the very least, pre- and post-test counselling at the first test should cover all the 
material in the Guidelines, but that at subsequent tests, injectors could be given 
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options about what should be covered. All information should be up to date and some 
aspects (like confidentiality) should perhaps be stressed on each test occasion. 
As long as they keep updating and letting us know the information that they 
have available or they've uncovered, great. But if it's going to be the same old, 
same old … and just a waste of time, effort and resources, let's not do it and 
spend that money in finding a cure. 
I would want them to ask me why I want the test done and what makes me 
feel that I am at risk. I would like questions like that, and I would also like 
him to tell me how to prevent them. Like people come and leave their syringes 
there and what I should do, and stuff like that. I think the GP should at least 
teach things like that. 
While there was strong support for the Guidelines to be flexible for those who were 
tested regularly, some things were seen to be important on every occasion: obtaining 
informed consent, reminders about confidentiality and notifiability and discussion 
about prevention of transmission to others if positive, or remaining uninfected if 
negative.  
Some thought that all Guidelines should be used on all occasions with all injectors:  
If I go and get tested every six months I know that I'm going to have to listen 
to all this stuff, but that's just something that I have to wear because it's for the 
benefit of someone else who's going to another GP that just sort of goes: ‘you 
know about hep C don't ya? Yeah. Ok well let's just get on with it. You know? 
Other comments related to the implementation of the Guidelines. Some respondents 
felt that more effort should be made to ensure that the Guidelines were implemented, 
and one suggested that a Handbook should be prepared for injectors, so they would 
know what a test could, or should, entail.  
Respondents were almost equally divided between saying that the TSP or a User 
Group/Hepatitis C Council, should do pre- and post-test counselling. Concern was 
expressed about GPs having enough time to do a thorough job: 
That would depend on the time limit I suppose of the GP, whether they are 
running two hours behind and really want to move on and whether they make 
any recommendations I suppose. 
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Many stressed that the relationship between the injector and their TSP was the critical 
factor, although some were clear that they would prefer counselling from someone in a 
User Group or other user-friendly organisation who would understand drug use. Most 
felt that the TSP should be the person to give results, and couched this in terms of an 
on-going relationship, although some believed that referral to a support agency was 
also important. But at least one person felt that it could be difficult to be honest with a 
GP:  
In my head anyway, that is like, 'what is this person thinking about me, I've 
shared a needle' … what happens before I even get there, is, 'I can't tell him 
this, I can't tell him that'. So even the honesty part is really hard, and being 
honest with your doctor has been a hard part of that. Because that fear of being 
judged about what you are doing, and your lifestyle and expectations – 
sometimes it is much easier just to have the blood taken and no questions 
asked. 
Almost half of the respondents admitted to some anxiety while waiting for test results, 
but most felt that this was normal, and little could be done to alleviate it, perhaps other 
than reduce the waiting time between test and results as much as possible.  
There were strong comments, however, about phlebotomy. Many injectors expressed 
considerable sensitivity about blood taking, some because they felt they could do a 
better job than a phlebotomist, and others because they were embarrassed by their 
track marks. Two respondents talked about these concerns in relation to their addiction 
to needles:  
I’m trying to get off drugs, and needles make me nervous: It was a lot easier to 
go for tests, because I was using as well, but like now trying to stay away from 
it, but knowing that I am going to get a needle, the rush and all that kind of 
stuff for me, my arms go stupid when I see a needle. And the whole thing of 
going in there and having it, which now even thinking about it, the needle part 
of it is hard. 
There were few suggestions for ways to alleviate these problems, other than a plea for 
understanding and sensitivity on the part of the TSP and a preference for not being 
sent to commercial pathology centres for blood taking. 
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Eleven of these 19 respondents said that their injecting practices had become safer as 
an outcome of testing. For some, this was a direct result of the information and 
counselling they received at the test; others because testing sensitised them to the 
disease, or they received a positive result:  
I tend to be more careful, more aware. Having BBV tests reminds me that 
catching it is a possibility, so I'm more careful. 
While they expressed interest in a range of sources of information including videos, 
pamphlets, books and Internet, some felt that there was no substitution for personal 
interaction with a knowledgeable professional.  
Almost all respondents thought that those with a positive diagnosis would need at least 
two appointments with their TSP: one for reassurance and support, and the second to 
deal with medical and other issues. A few felt that they would be so shocked they 
would need some ‘monitoring’ in the first few days after diagnosis.  
Yes, you have to go away and come to grips with the fact that you have it, 
then you should come back and find out what this really means now. You can't 
come to terms with that straight away. 
There were few other suggestions for improvement to the Guidelines. There were, 
however, a range of comments about implementation: many felt that there was little 
point in having well developed Guidelines if these were not followed by TSPs.  
Hepatitis B vaccination  
Almost all respondents thought that vaccination was a good idea, although only seven 
had been vaccinated and three had incomplete vaccinations. One went so far as to say 
that all those who had had a negative hepatitis B test should be compulsorily 
vaccinated. However, one vaccinated respondent understood that this might not be a 
priority for some injectors:  
You're so preoccupied with getting the next hit, that what's the point of going 
to the doctor? It is only going to waste time and money. I may as well just go 
out and get on, then I can relax and watch some telly. It is a completely 
different lifestyle when you are using every day. It is very hard core. 
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The various reasons for not being vaccinated related to “not getting round to it”; not 
knowing much about it; not being sure it was available for free; and having some 
concerns about vaccination as a medical procedure.  
When respondents were asked what they considered to be the ideal service for 
vaccination for injectors, a number of different models were proposed. Most responses 
specified, however, that the service should be free. Other suggestions were that the 
service should be well advertised, the regime should be accelerated, and patients 
should be reminded to return. Generally, the service attached to the local Needle and 
Syringe Program (WASUA) was considered to be the most attractive by most 
respondents.  
In-depth Interviews with Health Professionals  
The injector data were used by the investigators and consultants in the development of 
the interview guide for health professionals (Appendix II).  
Twenty one interviews were conducted with TSPs and key informants. Twelve TSPs 
were interviewed. For the purposes of this study, TSPs were defined as people who 
conducted and/or ordered blood borne virus tests for injectors. Test service providers 
were recruited from a range of areas, including treatment agencies (50%), needle and 
syringe exchange programs (17%) and general practitioners (33%). Nine key 
informants (KIs) were interviewed. For the purposes of this study, KIs were defined as 
people who had a professional opinion about the efficacy of pre- and post-test 
counselling for BBV testing. Key informants were recruited from a range of areas, 
including peak bodies representing the interests of injectors, (56%) hospital based 
liver clinics (22%), one sexual health clinic (11%) and one drug and alcohol 
information service. (11%).  
Respondents from this phase of the study are referred to collectively as “health 
professionals”. Some questions were asked only of TSPs or KIs, and their responses 
are attributed accordingly.  
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Experience and involvement in BBV testing 
Six health professionals had been working in area of BBVs for less than 2 years, four 
for 3 – 5 years, four for 6 – 10 years and seven for more than 11 years. Test service 
providers with special work related interests nominated illicit drug use or issues 
related to illicit drug use such as BBVs and methadone. Sexually transmitted diseases, 
psychological medicine and working with young people or children were also 
nominated. Most had first conducted or ordered a BBV test within the last 10 years. 
The number of BBV tests which TSPs estimated they had ordered/conducted in the 
past year ranged from 5 – 1 000 (average 253). The majority of TSPs conducted their 
own pre- and post-test counselling and some of these also conducted phlebotomy for 
tests. Other BBV involvement included providing education about BBVs in a context 
other than pre- and post-test counselling. 
Health professionals were asked what sort of BBV training, if any, they had received 
in their work. The majority had learned on the job, with half of these receiving specific 
training related to BBVs. Of those who learned on the job, most people learned by 
talking to colleagues, accessing resources and/or attending conferences. One had 
received specific training and another non-specific training relating to BBVs outside 
of their workplace.  
Scenarios  
Test service providers were presented with two scenarios relating to hypothetical 
requests for BBV tests and asked what they would do in each situation. Scenarios were 
adapted slightly to suit the type of agency represented by each TSP. Responses to the 
scenarios have been categorised in terms of the NHMRC Guidelines (Figs 3 and 4).   
KIs were not asked to respond to the scenarios but were given a copy of the NHMRC 
Guidelines and asked to provide feedback on them. 
The responses from TSPs and KIs are summarised below. In interpreting these data, it 
is important to note that TSPs did not have a copy of the NHMRC Guidelines to refer 
to whilst responding to the scenarios. Test service providers were prompted by the 
interviewer about confidentiality and notifiability, as this was identified as a key issue 
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by injectors in the first phase of the study, but were not prompted about any other part 
of the Guidelines.  
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17 year old female 
New patient 
Says she has been injecting speed for about 6 months 
Very anxious about her speed use 
Her boyfriend is 24 and has been injecting drugs for about 5 years 
Has never been tested for BBVs 




35 year old male 
A regular patient of yours for the past 2 years. 
He has been injecting heroin on a regular basis since he was 19. 
Steve has a BBV test approximately once every 6 months. 
For the past 2 years, you have been the sole provider of Steve’s BBV tests. 
To date, all of Steve’s BBV test results have been negative 
Presents saying that he’s due for his 6 monthly BBV test 
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Figure 5: Scenarios for TSPs 
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Test Service Providers’ and Key Informants’ responses in relation to  NHMRC Guidelines (see Figs 3 and 4, pp. 24-25).  
 
NHMRC Guideline 1.1:  Pre-test counselling should assess risk  
Scenario A: TSPs Scenario B: TSPs Key Informants 
Many TSPs indicated that they would 
assess Rebecca’s risk for BBVs before 
commencing testing. The majority 
indicated that they would ask about 
sharing injecting equipment. Most of these 
TSPs did not specify what type of 
equipment they would ask her about but 
several indicated that they would specify 
whether she shared fits, filters, spoons or 
water. 
A similar number of TSPs indicated that 
they would ask whether she practiced safe 
sex. However, a significant percentage 
indicated that they would not conduct any 
risk assessment at all or that they would 
assume that Rebecca was at risk of BBVs 
because of her injecting drug use.  
Several TSPs indicated that they would 
ask Rebecca to describe her injecting 
technique and would also ask her about 
other forms of blood exposure such as 
household exposure. A small number of 
TSPs indicated that they would attempt to 
establish rapport with Rebecca at this 
stage 
Most indicated that they would assess risk by asking whether Steve shared injecting 
equipment. Approximately half of these specified that they would ask whether he shared 
needles and half did not specify what type of equipment they would ask him about. Several 
TSPs indicated that they would question Steve about his continuing drug use and his continued 
exposure to risk.  
“Of course…it’s very rare for people to sort of cross their heart and say they’re at 
absolutely no risk. So … coming regularly for testing every six months isn’t actually 
responsible. It is in one way, but it isn’t really in the long term. The long term thing is not 
to have put yourself at risk in the first place.”  
A common theme amongst TSPs was that they would be less thorough with an assessment of 
risk for Steve.  
Several TSPs indicated that they would “touch base” with Steve and ask whether anything had 
changed since his last test.  
“Well I’d probably be a bit slack about the interview, if I was being really honest.”  
One TSP indicated that they would provide new and up-to-date information about hepatitis C 
at this time. Only one TSP indicated that that would be more thorough with a scenario such as 
Steve's than they would be with a naive user such as Rebecca. 
“I’d be a bit more … firm with him and say…’you keep using and why are you having a 
BBV test, are you doing some unsafe practices.’ I’d be a lot more thorough I suppose.”  
Other topics that TSPs indicated they would mention as part of an assessment of risk for Steve 
included his sexuality, lifestyle, whether he practiced safe sex, whether he had experienced any 
symptoms of hepatitis C and his drug use. 
Key informants indicated that 
assessing risk was of primary 
importance, particularly in 
terms of providing relevant 
harm reduction information 
post-test. In order for risk 
assessment to be successful, 
some key informants indicated 
that this needed to be carried 
out in an observably non 
judgmental way with attention 
to language detail and without 
using simple slogans such as 
"sharing a fit," which could be 
misleading or stigmatising 
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NHMRC Guideline 1.2:  Pre-test counselling should provide clinical information about the virus 
Scenario A: TSPs Scenario B: TSPs Key Informants 
All TSPs indicated that they would provide some sort of clinical 
information about BBVs to Rebecca. This information ranged from details 
of how the viruses are transmitted and how to reduce the risk of 
contracting them to information about treatment and the nature and 
symptoms of the diseases.  
Some TSPs indicated that they would phrase the clinical information 
based on what the injector already knew about BBVs and aim to dispel 
myths about them. One TSP indicated that the clinical information they 
provided was based on the risk assessment which they had conducted with 
the injector.  
A minority of TSPs indicated that they would only provide limited clinical 
information and that they would provide more detail if the result were 
positive.  
“I say that it's a risk and that it's a liver disease and that it can have 
quite serious complications. But I wouldn't go into great detail. 
Not until I got some positive result." 
The majority of TSPs indicated that they would 
not provide much clinical information about the 
borne viruses because Steve would have already 
heard this at previous tests.  
“I wouldn't tell him anything about the 
viruses because I would have already 
said that 3 million times.”  
Other responses included finding out what Steve 
already knew about BBVs and dispelling myths 
or giving up to date or new information. 
In terms of providing clinical information, 
key informants felt that this was an 
important part of pre-test counselling, 
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NHMRC Guideline 1.3  Pre-test counselling should provide information about the test and the possible consequences of testing, 
including confidentiality and notifiability 
Scenario A: TSPs Scenario B: TSPs Key Informants 
A significant number of TSPs indicated that they did not provide information, or did not always 
provide information, about notifiability. Several of these indicated that they did not tell injectors 
about notifiability prior to the test because they had no choice about notifying the results to the 
Health Department and the information was statistical and confidential. Other TSPs indicated that 
they would talk about notifiability with the injector once their result was positive or if they believed 
that there a high risk of a positive result.  
“Notifiability? I’m really slack with that…’cause we do it with a closed system. We don’t get 
names and addresses.”  
Very few TSPs indicated that they always informed injectors about the confidentiality of the testing 
process. Some believed that injectors assumed confidentiality and it was therefore not necessary to 
state this. Only one asked clients to sign a consent form which included information about 
confidentiality, notifiability and the implications of a positive or negative test result.  
In terms of the information provided about the test itself, some TSPs indicated that they always told 
injectors about the type of test and the window periods for returning a positive result for BBVs. 
Other information which was given at this point included information about false positives, how long 
it takes for results come back, that results would be given face-to-face and who they needed to 
inform (if anyone) if they returned a positive result.  
As per Scenario A in terms of the 
types of information that would be 
covered.  
However a number of TSPs 
indicated that they would not 
spend much time talking about 
these issues at this test because 
they would have been covered 
during previous tests.  
“The usual things… 
I’d be a little less 
careful, because I’d 
assume we’ve 
discussed it with him 
before.”  
 
Key informants indicated very 
clearly that information about 
confidentiality and notifiability 
should always be stated before 
each blood borne virus test. 
This was seen as critical in 
establishing informed consent. 
 
NHMRC Guideline 1.4 Pre-test counselling should provide information on testing benefits 
Scenario A: TSPs Scenario B: TSPs Key Informants 
No TSPs indicated that they would discuss this 
issue with Rebecca.  
 
No TSPs indicated that they would discuss 
this issue with Steve. 
 
KIs’ opinion was divided about the merits of this guideline and the 
earlier guideline about enabling the patient to decide whether to be 
tested. Some felt that these guidelines duplicated each other’s 
meaning or that their meaning was not clear.  
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NHMRC Guideline 1.5 Pre-test counselling should establish the ability to give informed consent 
Scenario A: TSPs Scenario B: TSPs Key Informants 
TSPs were asked whether Rebecca's age (17 years) would be an issue in 
deciding whether to conduct her BBV tests. Most indicated that her age 
would not be an issue but that they would make more of an effort to check 
that she understood the concept of informed consent and that she was 
stable enough to receive the results. Some TSPs indicated that they would 
check how independent she was from her parents and would encourage 
her to tell her parents what was happening.  
In terms of the form of consent required, some TSPs asked for specific 
verbal consent and one asked injectors to sign a consent form. In one case, 
injectors signed a form for release of information about the test from the 
testing doctor to the treatment agency but not for the test itself.  
One TSP indicated that consent was implied when the injector accepted 
the written referral form for the test. One TSP indicated that injectors were 
sometimes intoxicated when being tested and/or giving consent for testing. 
The majority of TSPs indicated that this type of issue 
would have been covered at previous tests, though 
this was not always specified. Several indicated that 
they would ask for verbal consent and one indicated 
that they would ask him to sign a written consent 
form. 
Key informants clearly indicated that 
health professionals have a 
responsibility to provide patients with 
sufficient information to decide 
whether to be tested, that is, to facilitate 
informed consent 
 
NHMRC Guideline 1.6  Pre-test counselling should enable the patient to decide whether they should be tested  
Scenario A: TSPs Scenario B: TSPs Key Informants 
No TSPs indicated that they would discuss this issue 
with Rebecca.  
No TSPs indicated that they would discuss this issue 
with Steve. 
KIs’ opinion was divided about the merits of this 
guideline and the guideline about providing information 
about testing benefits. Some felt that these guidelines 
duplicated each other's meaning or that their meaning 
was not clear. Other key informants felt that this 
guideline represented a forgone conclusion. 
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NHMRC Guideline 1.7 Pre-test counselling should identify support available to the patient 
Scenario A and B: TSPs Key Informants 
The majority of TSPs did not mention identifying support as one of the activities that they would 
undertake during pre-test counselling. 
Of the few TSPs who indicated that they would identify support, some indicated that they would 
only do this if the injector were at high risk of a positive result.  
Other TSPs indicated that they would identify support in a general way and in the case of Rebecca 
would assess her relationship with her boyfriend or encourage her to tell her parents what was 
happening. 
While key informants recognized that identifying sources of support 
was an important part of the testing process, they also recognized that 
this could sometimes be a complex issue which may be difficult to 
discuss with a TSP. It was also recognized that additional support 
might be needed between pre- and post-test counselling sessions. 
 
NHMRC Guideline 1.8 A written summary of the information covered in the pre-test counselling should be given, preferably in 
their native language 
Scenarios A and B: TSPs Key Informants 
The majority of TSPs indicated that they provided some form of information, usually in the form of the hepatitis C 
pamphlets or other BBV pamphlets published by the Health Department of WA and the Hepatitis C Council of 
W.A. Several TSPs indicated that it was often difficult to find the pamphlets when they wanted to give them to an 
injector. Only one TSP indicated that they went through the pamphlets with the client. Some TSPs expressed 
concern that injectors would not read written information which was given to them.  
A significant percentage of key informants indicated 
that written information in the form of pamphlets was a 
good way to provide information. 
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NHMRC Guideline 1.9 Arrangement for a post-test counselling appointment should be made during pre-test counselling 
Scenario A: TSPs B: TSPs Key Informants 
TSPs spoke of a wide range of practices in relation to giving test results and setting up appointments to receive results. 
Several indicated that they would give the results of the blood tests at the injector's next appointment, which would take 
place regardless of the test result in relation to receiving ongoing treatment or a second hepatitis B vaccination.  
Some indicated that they would give results over the phone on occasions but preferred injectors to come in and receive 
results face to face. Other practices included giving all results for all types of blood tests and all types of results over the 
phone, or sending a letter to people who had received a positive result asking them to return to the agency to receive 
their results. 
“Actually I give all results over the phone, especially for patients I know. I’ve never had [an HIV result] so I’d be 
very hesitant about giving them over the phone. Hep C, well I wouldn’t hesitate about giving over the phone. …I 
think its better to give them the results as soon as you’ve got them, rather than tell them that you’ve got the results, 
come and make a new appointment. And then they get themselves all worried.” 
One TSP indicated that if they perceived the person was at high risk of receiving a positive result they would set up a 
face-to-face appointment to receive results, but this would not necessarily occur if they considered the person was at low 
risk of returning a positive result. 
A small number of TSPs stated that they would not give results over the phone in any situation and that clients were 
always informed during pre-test counselling that results were given face-to-face regardless of the result. 
As per Scenario A. 
One TSP indicated 
that it was unlikely 
that an appointment 
for Steve to come 
back and receive 
results would be 
made, because a 
negative result would 
be assumed.  
 
Key informants indicated 
that results should be 
given face-to-face in the 
majority of cases, but 
that there should be some 
discretion for the test 
service provider to divert 




NHMRC Guideline 2.1  Post-test: Counselling should always be in person no matter what the reason for the test or whether the 
result is positive or negative. Refer. 1.9 
NHMRC Guideline 2.2  Post-test :Ensure that the patient understands the meaning and implications of the test result. Refer to Post-
test counselling, positive/negative result. Refer 3.1, 4.1, 4.2 
NHMRC Guideline 2.3 Post-test: ensure that appropriate referrals and psychosocial interventions occur if required. Refer to Post-
test counselling, positive/negative result. Refer 3.1, 4.3, 4.4.  
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NHMRC Guideline 3.1  Post-test for a negative result: Counselling should provide information to prevent exposure to the virus.  
3.2 The individual should be assisted to adopt relevant skills to remain infection free. 
Scenarios A and B: TSPs Key Informants 
Responses for both scenarios were quite similar, with TSPs indicating that they would be most likely to talk about 
how to reduce the risk of contracting BBVs in the future. More TSPs indicated that they would provide this 
information for Scenario A, with the assumption being that Steve would already know much of this information 
from previous tests.  
Other responses made by TSPs in this section included the fact that they would stress to injectors that it is better to 
be risk free than to keep getting tested. In the case of Rebecca, several TSPs indicated that they would also 
encourage her boyfriend to be tested for BBVs.  
“A lot of people think that a negative test condones their behaviour, but I would take pains to say that she’s 
been very lucky and … [would] go through the safe injecting etc, spoons and injecting talk.”  
No TSPs indicated that they would refer either Rebecca or Steve for further information or support following a 
negative result.  
A minority of TSPs indicated that they would explain the meaning of a negative test.  
Several TSPs indicated that follow-up of negative results was often problematic, particularly due to limited 
resources at the agency. Several TSPs indicated that they would spend less time counselling Steve for a negative 
result than they would Rebecca.  
“He knows the risks. I don’t think he’d want you to make too much of a song and dance about it.”  
Key informants recognized the importance of post-test 
counselling in providing harm reduction information. 
They recognized that people might be more open to 
change in a crisis. However some key informants also 
expressed the view that the way in which this 
information was provided was critical and that test 
service providers should use a problem-solving 
approach and avoid giving an insensitive lecture or 
asking patients to justify themselves or their actions. 
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NHMRC Guideline 4.1  Post-test for a positive result: Immediate counselling should be provided. 
Scenario A: TSPs Scenario B: TSPs Key Informants 
Several TSPs recognised that a diagnosis of hepatitis C can be 
devastating to some people and that it is difficult to take in information 
immediately after learning of the diagnosis.  
Other TSPs indicated that in their experience injectors were often not 
surprised or distressed at receiving a positive diagnosis.  
“I’ve never known anyone who’s terribly reactive about 
knowing that they’ve got hep C.” 
Several TSPs indicated that after two years they 
would have good rapport with Steve and that there 
would not be much else that they needed to say at this 
point.  
“I wouldn’t have thought that there’d be 
that much left to say to be perfectly honest. 
You can try and break the news and see 
how he takes that.” 
Key informants felt that immediate 
counselling was one of the most important 
factors in post-test counselling for the 
positive patient.  
Key informants acknowledged the shock 
that many people experience when 
learning of a positive result. 
 
NHMRC Guideline 4.2 Post-test for a positive result: Support and information to prevent transmission should be provided. 
Scenarios A and B: TSPs Key Informants 
TSPs demonstrated that they would approach a positive result for Rebecca or Steve in similar ways. In both cases, 
a majority of TSPs indicated that they would provide clinical information about the virus, information about 
transmission, further blood tests and a follow-up appointment. Other likely topics for post-test counselling 
included information about lifestyle changes and possibly written information. 
TSPs were more likely to explain the results to Rebecca than they were to Steve and TSPs indicated that they 
would address a wider range of information topics with Rebecca than they would with Steve. 
Key informants acknowledged that the TSPs lack of 
time and the patient’s shock at learning of a positive 




NHMRC Guideline 4.3  Post-test for a positive result: The extent of personal support should be assessed. 
Scenarios A and B: TSPs Key Informants 
Several TSPs indicated that they would help Rebecca and Steve to identify possible forms of support. Key informants did not comment specifically on this 
area of the guidelines.  
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NHMRC Guideline 4.4  Post-test for a positive result: Referral to external sources of support such as longer term  counselling or a 
local hepatitis C Council should occur.  
Scenarios A and B: TSPs Key Informants 
TSPs were likely to refer the person to the Hepatitis C Council of WA for further information or support.  
Opinion about referring for counselling was divided. Some TSPs indicated that they would refer for further 
counselling and support if they considered this necessary while others indicated that although they might refer for 
treatment or further information they preferred to conduct their own counselling.  
Several TSPs indicated that they would refer Rebecca and Steve for hepatitis C treatment. 
Key informants acknowledged that referral was one of 
the most important functions of post-test counselling 
for a positive result.  
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Implementing the NHMRC Guidelines for Pre- and post-test Counselling 
Following discussion of the scenarios, TSPs were given a copy of the NHMRC 
Guidelines to consider. Both TSPs and KIs were asked to comment on the 
implementation of the Guidelines and more general issues about BBV testing with 
injectors, as below.  
Most agreed with the content and intent of the Guidelines. Very few said they felt it was 
necessary to refer to the Guidelines every time a test was ordered, as they felt they had a 
good knowledge of their content.  
I’m aware in a very big way of the usual suggestions as to pre- and post-test 
counselling, but I suspect it has become a little routine for me, because I’m not 
perhaps discussing it too much with the patient. 
Many health professionals indicated that the Guidelines did not need to be, and should 
not be, followed in detail for every BBV test. The main barrier to carrying out effective 
pre- and post-test counselling was felt to be the lack of time, with the length of the 
average appointment ranging from 15 - 60 minutes.  
Basically … some of it you miss with them and there’s some that you overdo 
with them, but I think it’s like seeing the person and about what’s happening for 
them. 
Opinion varied about the use of the word “counselling” in the Guidelines. Some felt it 
was appropriate, some preferred terms like “pre-test information” and some felt that it 
was not an issue. 
It’s almost getting into the therapy side of counselling a bit, there’s a bit of an 
overlap and the problem is that there isn’t the time for the therapy side. 
The majority of BBV tests ordered by TSPs were simultaneous tests for hepatitis C, 
hepatitis B and HIV/AIDS. Most TSPs said they felt they were doing all that they could 
in relation to BBV testing.  
In terms of the physical form of the Guidelines, health professionals indicated a wide 
range of preferences, from CD ROM or web based designs to laminated charts or posters 
or the existing paper based form. Several indicated that a variety of forms would be 
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needed to meet the different needs of TSPs. Some also commented that the TSPs who 
were likely to conduct thorough pre- and post-test counselling would do so regardless of 
the form of the Guidelines and that TSPs who were not going to conduct thorough pre- 
and post-test counselling would not change their practices if the Guidelines were 
presented in a different format. 
BBV testing and the role of the TSP 
Test service providers were asked when they were most likely to suggest testing to an 
injector. The most common response related to the level of perceived or actual risk of the 
injector contracting BBVs. A significant number of TSPs indicated that they always 
suggested BBV testing, particularly when working with people who injected drugs. Other 
reasons for suggesting BBV testing related to the person’s testing history, their level of 
knowledge about hepatitis C and admission to a residential treatment program.  
Test service providers were asked how they would respond in a situation where 
somebody repeatedly requested testing when it was not deemed clinically necessary. 
Most TSPs indicated that they would agree to test the injector. Some of their reasoning 
included the fact that it was an opportunity for harm reduction information to be given, it 
was an important means of maintaining rapport and /or that someone asking for test was a 
good enough reason for it to be carried out. A number, however, indicated that they 
would try to dissuade the person from being tested and/or explore the reasons why the 
person wanted to be tested. Other responses included assessing the individual situation, 
not retesting, and testing for free once but then charging for subsequent tests if not at risk. 
Reasons given for not retesting somebody in this situation included issues related to 
agency resources and a belief that retesting was unlikely to result in any change to long 
established risk practices.  
 In regard to retesting, one test service provider expressed the dilemma which many TSPs  
experienced in relation to retesting. 
I probably would [retest]. I could feel a little bit guilty about it because it's 
costing the taxpayer a certain amount of money. I think it's very important that I 
maintain a good rapport with him and I might discuss why he thinks he needs a 
test at the moment. It's difficult enough to get people to come for tests and if 
they're asking for a test then it makes sense to give it to them. 
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Another TSP  talked about the need to find out why an injector continued to request 
testing. 
I think you've got to explore that, you've certainly got to find out what's behind 
his fears. There may be something else behind his anxiety, not necessarily having 
hepatitis, the danger of hepatitis C or HIV... You can sort of fob somebody off all 
the time to have this done. But then you think, well I'm actually missing an 
opportunity here. 
Health professionals were also asked how often injectors should be tested for BBVs. For 
hepatitis C, opinion ranged from three months-12 months, with the majority believing 
that hepatitis C testing should occur once every six months. Not all health professionals 
commented about testing for hepatitis B and HIV, but those who did indicated that testing 
should occur once every three months. Several health professionals thought that the BBV 
testing interval should depend on the injector’s current level of risk while others felt that 
it should occur on an individual basis. Other options included testing on commencement 
and completion of a residential treatment, an interval of approximately eight weeks.  
Factors which affected health professionals’ decision about how often injectors should be 
tested for BBVs included considerations about window periods, working with clients 
who were sometimes transient, the level of risk currently being experienced by the 
injector, the cost of testing and the wishes of the person being tested.  
One health professional summarised his view about HCV testing thus. 
Six monthly is not unreasonable for someone who's injecting on a regular basis. I 
think 6 months is probably a reasonable compromise between frequency, cost and 
likelihood of getting a positive. 
Health professionals were asked about the role of BBV testing particularly in preventing 
the transmission of BBVs. They were asked to indicate whether they felt that BBV 
testing was a medical-psychosocial issue or whether it was a medical issue only. The 
majority of health professionals thought it was a medical- psychosocial issue.  
There were a number of positive associations with BBV testing. The most commonly 
mentioned were factors relating to information, education and awareness about BBVs. 
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Blood borne virus testing was seen as an opportunity to provide information and 
education and to raise awareness about the transmission of BBVs.  
Approximately one quarter of health professionals stated explicitly that BBV testing was 
a good vehicle for prevention. The opportunity for harm or risk reduction was commonly 
mentioned. Health professionals also indicated that BBV testing was an opportunity to 
talk about risk, to identify triggers or situational contributors to risk and to develop 
strategies with the injector for avoiding risk in the future. 
A smaller number of health professionals believed that BBV testing was an opportunity 
to achieve changes in attitude, particularly in terms of breaking down blasé attitudes 
about transmission of BBVs or beliefs about re-infection and co-infection. A similar 
number of health professionals also talked about the results of a BBV test changing 
people's risk behaviour. This could take the form of the anxiety experienced while 
waiting for results motivating the person to reduce risk behaviour in the future or the 
injector being keen to remain negative for BBVs after receiving a negative result.  
Several health professionals indicated that they felt testing had a role in providing 
reassurance to people who injected drugs about their BBV status. Several also suggested 
that pre- and post-test counselling had the potential to help establish rapport between 
TSPs and those being tested. One suggested a link between establishing rapport and pre- 
and post-test counselling as a tool for prevention.  
If testing can encourage doctors to talk to people who inject drugs like human 
beings that's an effective prevention tool. 
Interestingly, only one health professional talked about the role of BBV testing in terms 
of detecting viruses and initiating treatment.  
There were a similar number of negative or cautious associations with BBV testing. 
Health professionals recognized that BBV testing was not always a priority for injectors 
and although it might present an opportunity for psychosocial intervention this might not 
be what the injector wanted at that time. Some concern was expressed that TSPs might 
attempt to provide more information than the injector was willing to receive.  
You can't expect the education if they're not interested in hearing the message. 
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Some health professionals were of the opinion that while BBV testing was a vehicle for 
prevention it was not necessarily the best vehicle. This related to the different settings in 
which BBV testing might take place and the variation which this might cause in the 
efficacy of pre- and post-test counselling.  
Some health professionals also recognized that although there might be good intentions 
to change behaviour immediately after receiving a negative result, achieving and 
maintaining long-term change was more difficult.  
My experience has been that... In theory people... have got a negative... and 
there's this huge relief and they perhaps change their behaviour … perhaps for a 
short time. And then gradually... they step backwards again. 
Another view was that being tested for BBVs too often (for example more frequently 
than once every three months) could actually increase risk behaviour. 
Some health professionals were more negative in their perceptions of BBV testing as a 
vehicle for prevention. Several felt that BBV testing was too late in the process to have 
any real impact and others indicated that information from users’ organisations and 
information in “Fit-packs” would work better than the pre- and post-test counselling 
associated with BBV testing. Another health professional made the point that testing 
injectors for BBVs was not the only opportunity to talk to them about ways to reduce 
their risk of contracting BBVs.  
Several health professionals did not believe there was a strong link between BBV testing 
and behaviour change. Some felt that access to clean injecting equipment was a much 
more effective prevention tool than BBV testing or pre- and post-test counselling. 
The behaviour is more about I reckon being in the wrong place at the wrong time 
without the right piece of equipment. You know what you're supposed to do, 
most people, but at the time if you haven't got access to it [then] the only option is 
‘OK I'll take the risk’ and then do it and afterwards they panic and think ‘oh shit, 
shouldn’t have done that.’ It's more about that than actually in the future, change, 
you know, but you can't have a fit pack with you 24 hours a day really, can you? 
 Another group of health professionals felt that it was more important to look at the 
broader issues around illicit drug use such as social, legal and psychological issues than it 
October, 2001  National Drug Research Institute 
Talking about testing 59 
was to focus on BBV testing as a means for prevention. One expressed the opinion that 
BBV testing was merely "a sop to the community."  
Health professionals were well aware of the need for hepatitis C prevention. Several 
expressed the view that hepatitis C was an epidemic which had huge consequences for 
the public health system in the future although a number also suggested that HIV/AIDS 
was still seen as more of an issue by people who injected drugs than hepatitis C. 
Health professionals were asked which type of agency or organisation was best placed to 
provide BBV testing and pre- and post-test counselling. Peer based agencies such as 
WASUA were clearly the preferred type of agency to provide BBV testing for injectors. 
General practitioners were the next preferred option. The next most popular option was 
for drug treatment agencies to provide BBV testing and counselling. Several health 
professionals indicated that there was a need to develop a specific service or outreach 
facility to provide BBV testing for injecting drug users. Others indicated that a multi 
disciplinary approach was most appropriate. 
In looking at these results, it is important to take into account that there was a very strong 
tendency for agencies to nominate their own type as the best place to provide BBV 
testing and pre- and post-test counselling. All the GPs who responded to this question 
maintained that GPs were best placed to undertake this counselling. All the health 
professionals associated with peer based programs suggested peer based programs were 
best placed to undertake this counselling and all the suggestions of treatment agencies 
came from health professionals who represented treatment agencies.  
As well as nominating which types of agencies were felt to be most appropriate to 
provide BBV testing, health professionals also indicated what they considered to be most 
important aspects of the provision of BBV testing. Many thought that people who 
injected drugs should have a choice about the type of agencies they accessed for BBV 
testing. Continuity in the agency and the staff member providing BBV testing and 
counselling was also considered to be an important issue. This was partly because 
continuing to see the same TSP over a period of time was seen as critical in establishing 
rapport between the TSP and the injector.  
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A number of agencies suggested that they currently experienced resource related issues in 
providing BBV testing and/or counselling, or that they would experience resource related 
issues if they were to expand into this area. The majority of health professionals who 
raised resource related issues suggested that more cooperation with other agencies could 
help them to overcome these problems.  
Health professionals expressed a range of opinions about the merits of each type of 
agency or organisation being involved in BBV testing and counselling. Some indicated 
that, in their experience, GPs and hospital clinics could be judgmental of people who 
inject drugs and that GPs did not provide enough counselling in the testing process. Other 
health professionals had positive perceptions about GPs providing BBV testing and 
counselling although some felt that GPs required more training in this area.  
Although peer based programs were most frequently nominated as the best type to be 
offering this kind of service, some health professionals were not aware of their existence. 
Hepatitis B vaccination  
Test service providers were asked if they would recommend hepatitis B vaccination for 
Rebecca and Steve, regardless of their BBV test results. The vast majority of TSPs 
indicated that they would recommend vaccination and one TSP indicated that if Rebecca 
and Steve were positive for hepatitis C then they would recommend hepatitis B and 
hepatitis A vaccination. Two TSPs said that their agency did not suggest or provide 
hepatitis B vaccination.  
All health professionals were asked what they considered to be the main barriers 
preventing the uptake of hepatitis B vaccination amongst injectors. The need to have 
three vaccinations over a period of time (usually six months) was considered to be a 
significant barrier for many injectors. A slightly smaller number of health professionals 
indicated that the cost of the vaccination was also a significant barrier, as was the fear or 
dislike of the intramuscular injection used for hepatitis B vaccination.  
I think the main thing is people’s time and the pain of the needle. And they’re 
worried about an immediate reaction after the needle. 
Other responses included the perception that injectors were in too much of a hurry at the 
time of the appointment to have the vaccination done and misconceptions about universal 
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hepatitis B testing. Several TSPs indicated that they did not suggest or offer hepatitis B 
vaccination through their clinic and others said that they did not think there were any real 
barriers to hepatitis B vaccination. 
PHASE 2 DEVELOPMENT OF AND FEEDBACK ON DRAFT GUIDELINES 
Development of Modifications to NHMRC Guidelines 
The data from Phase I were discussed by the consultants and investigators in the 
development of proposed modifications to the Guidelines. These modifications, which 
are described below, take the form of flexible guidelines, with some elements that are 
considered essential (part of a minimal set) and some negotiable. Essential guidelines are 
defined as those which should be included in every pre- and post-test counselling session 
regardless of the person's testing history, relationship with the TSP, knowledge of blood 
borne viruses or current situation. Negotiable guidelines are defined as those which are 
not essential for every patient. Whether or not they would be included in a particular test 
could be negotiated between the person being tested and the test service provider and 
would depend on the person's testing history and knowledge of blood borne viruses.  
In the following section, considerations which were used in the development of the 
modified guidelines are described.  
1. Pre-test counselling should:  
1.1 Assess risk 
 Injectors and TSPs agreed that assessing risk was an important part of pre-test 
counselling. However, there was significant variation reported in the depth of risk 
assessment, from "do you share fits?" to detailed discussion of injecting technique. This 
indicated the need for some standardisation. The consultants were somewhat divided 
about the value of this, given the resulting increase in length of the guidelines. It was 
recognised by the majority of respondents, however, that risk practices and knowledge 
about BBV transmission alter over time. Thus it was felt that assessing risk needed to be 
part of the essential set of guidelines, regardless of the number of times someone had 
been tested.  
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1.2 Provide clinical information about the virus 
Whilst providing clinical information was considered by injectors and health 
professionals to be an important part of the testing process, the majority of respondents 
recognised that it was not appropriate to deliver the same clinical information at every 
test. Injectors expressed a desire to hear new information, but not to receive the same 
information at every test. Consultants also recognised that some flexibility was required 
in order for the guidelines to be workable. Thus it was suggested that this guideline be 
negotiated in terms of the injector's testing history and their knowledge of BBVs.  
1.3 Enable the patient to decide whether they should be tested  
Injectors and TSPs had difficulty in understanding how this guideline differed from other 
guidelines such as 1.4 and 1.5. Test service providers did not volunteer this topic as one 
which they would include. The fact that many injectors ask to be tested complicates the 
application of this type of guideline. The intent of this guideline is probably to ensure that 
the injector has sufficient information and opportunity to provide informed consent for a 
BBV test. Informed consent was considered by many respondents to be the key goal of 
pre-test counselling. Thus, while this guideline represents an important stage in pre- and 
post-test counselling, the research indicated that it might be more effective if it was 
incorporated with guideline 1.6 to form a new guideline which represented the gaining of 
informed consent. This new guideline would be part of the essential set of guidelines.  
1.4 Provide information about the test and the possible consequences of testing, 
including confidentiality and notifiability 
All respondents tended to be unclear as to what "information about the test" might 
include. Thus there would be some value in specifying what this information should 
cover. The provision of information about confidentiality was relatively uncontroversial, 
with the majority of respondents indicating that this part of the guidelines was currently 
followed and should continue to be followed in the future.  
The provision of information about notifiability was more controversial. A significant 
percentage of injectors indicated that they were not aware of notifiability arrangements 
and that they would have liked to be informed of them. The majority of injectors saw this 
as a courtesy and as part of giving informed consent. No injectors indicated that they 
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would have refused a BBV test if they had known about notifiability - most were 
reassured once they were informed that the information was confidential and anonymous. 
Regardless of this, they still preferred to be informed about notifiability before giving 
consent. Health professionals were divided in their response to this element of the 
guidelines. Several TSPs expressed doubts about the wisdom of informing injectors about 
notifiability, given that the information was essentially statistical and confidential and 
that notifiability was mandatory. These doubts appeared to contribute to a belief that 
injectors might refuse to be tested if they knew about notifiability and/or that there was 
nothing to be gained by telling them because it could cause them to be concerned by 
something over which they had no control. Other health professionals believed that it was 
important to inform injectors about notifiability in order to give them all the information 
they needed to provide informed consent. Consultants were also divided about the value 
of informing injectors about notifiability.  
In considering these opposing points of view, three factors were taken into account. The 
first of these was that no injectors indicated they would have refused to be tested if they 
had known about notifiability. The second was that BBV testing is usually not urgent. If 
an injector had concerns about notifiability, there would normally be the option for them 
to consider the issue at their leisure before deciding whether or not to be tested. The third 
was that facilitating informed consent was clearly seen by all respondents as a key goal of 
pre-test counselling. In order to achieve "true" informed consent we felt it was necessary 
to inform injectors about notifiability.  
All respondents (and some consultants) had difficulty in distinguishing between this 
guideline and guideline 1.5. In order to avoid ambiguity and repetition, it was 
recommended that this guideline be incorporated with 1.5 to create one which 
represented the provision of necessary information prior to gaining informed consent. 
This new guideline would be part of the essential set.  
1.5 Provide information on testing benefits 
Respondents and consultants had difficulty identifying what this guideline actually 
meant. No TSPs indicated that they would "provide information on testing benefits" in 
either scenario. It was considered that merging this guideline with 1.4 would clarify and 
simplify the pre-test counselling process and create a guideline which represented the 
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provision of necessary information prior to gaining informed consent. This new guideline 
would be part of the essential set.  
1.6 Establish the ability to give informed consent 
Respondents and consultants agreed that informed consent was a key aim of pre-test 
counselling, so much so that some respondents suggested that pre-test counselling should 
be called "obtaining informed consent". Health professionals indicated that they would 
cover this issue, although more attention was paid to it in Scenario A, which related to the 
first BBV test of a girl aged under 18 than in Scenario B which involved testing an 
experienced injector. Most health professionals indicated that the most appropriate way to 
gain informed consent was verbally. Written consent was seen by both health 
professionals and injectors as potentially compromising of confidentiality and/or 
anonymity. Confusion arose around whether somebody who was requesting a test still 
needed to give informed consent; an issue which should be clarified in the guidelines. It 
was recommended that this guideline be incorporated with guideline 1.3 to form a 
guideline which represented the gaining of informed consent. This new guideline would 
be part of the essential set.  
1.7 Identify support available to the patient. 
Some respondents, particularly injectors, recognised that determining a person's level of 
support prior to a BBV test was a critical part of managing a positive result. A significant 
percentage of TSPs, however, did not include identifying support as one of the activities 
they would undertake in responding to the scenarios. Respondents also recognised that 
assessing a person's level of support could be a complex process which would vary 
significantly between individuals. Another suggestion was for people to bring a support 
person to the post-test counselling session, regardless of the result. Another option was 
only to identify support as part of post-test counselling for a positive result, or only to 
identify support if somebody was thought to be at high risk of returning a positive result. 
In discussion with the consultants it was suggested that while assessing a person's level of 
support was important, in some situations it could be negotiated between the TSP and the 
injector.  
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1.8 Provide a written summary of the information covered in the pre-test 
counselling preferably in the patient’s native language 
 A wide range of opinions about the value of providing written information as part of pre-
test counselling was expressed. These opinions related mainly to the literacy of people 
being tested and the relevance and availability of written information. It was assumed that 
written information meant pamphlets and brochures about BBVs, such as those published 
by the Health Department of WA or the HCCWA. The broad range of opinions and the 
frequency with which some injectors are tested indicated that it would be not be advisable 
or practical for it to be deemed essential to provide written information on each testing 
occasion. Some injectors also indicated that they would find information which was 
presented by means of video or internet easier to access and/or understand and some were 
concerned that written information should not replace personal interaction. Several 
consultants raised concerns about the availability and appropriateness of materials which 
had been translated into other languages and about the provision of information for 
people with low literacy levels. While not a focus of this study, it is an issue which 
warrants further attention. Thus it was suggested that the provision of written information 
be negotiated based on the person's testing history and knowledge about BBVs.  
1.9 Make arrangements for a post-test counselling appointment  
Respondents expressed a broad range of opinions about the wisdom of always receiving 
results in person. One of the chief concerns which was raised related to the injector 
telephoning for test results and being informed that they had to make an appointment to 
receive results, thus occasioning anxiety. Adhering to this guideline would help to reduce 
that anxiety because injectors would know that regardless of whether it was negative or 
positive they would still need to see the TSP to receive the result of their BBV test. It was 
also recognised that giving BBV test results in person is often facilitated by the injector 
returning to see the TSP in relation to another matter, for example drug treatment. Some 
respondents indicated that it was not always possible or desirable to give results face to 
face. This issue was discussed with the consultants and despite these varying opinions, it 
was decided that it would be preferable to keep this as part of the essential set of 
guidelines in order to demonstrate the importance of giving results in person.  
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2. Post-test counselling should: 
2.1 Always be in person no matter what the reason for the test or whether the result 
is positive or negative 
Bearing in mind the difficulties associated with giving results face to face, as discussed in 
1.9, it was decided that this guideline should remain as part of the essential set of 
guidelines.  
2.2 Ensure that the patient understands the meaning and implications of the test 
result 
While this guideline was seen by respondents and consultants as being an important part 
of post-test counselling, it was also considered to be superfluous in some situations, for 
example where a person had consistently returned negative results over an extended 
period of time. It was also thought by consultants that it could be addressed by the 
provision of written information. Consultants also identified potential difficulties for the 
TSP in recognising whether somebody understood the test result or not. Thus it was 
considered that this guideline could be negotiated based on the person's testing history, 
relationship with the TSP and current situation.  
2.3 Ensure that appropriate referrals and psychosocial interventions occur if 
required 
This guideline was considered by respondents and consultants to apply only in the case of 
positive results. We therefore recommended removing it from this position and it is 
further discussed under 4.3 and 4.4. 
3. If patient is negative:  
3.1 Counselling should provide information to prevent exposure to the virus.  
3.2 The individuals should be assisted to adopt relevant skills to remain infection free 
Provided that the information was presented in a non-judgemental and interesting way, 
the majority of respondents supported the inclusion of this guideline. Most TSPs 
indicated in responding to the scenarios that they would address this issue, and a 
significant percentage of injectors indicated that they would find such information useful. 
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It was suggested that basing this information on the risk assessment which was conducted 
pre-test would increase its relevance for the injector. It was thought that this guideline 
should be retained as part of the essential set.   
4. If patient is positive:  
4.1 Immediate counselling should be provided 
Providing immediate counselling was seen as the key role of the post-test consultation. 
The strong reaction of injectors to both actual or hypothetical positive results indicated 
that immediate counselling would be paramount. Some health professionals also 
recognised that a diagnosis of hepatitis C could be devastating. The majority of 
respondents indicated that in the shock of receiving a positive diagnosis it would be 
difficult to absorb information. Thus it was considered that a two-stage positive result-
giving process could be of benefit, with the first stage including immediate counselling 
and the second stage including medical and other consultations and referral. Whilst this 
concept had support from most respondents, it was not supported by all consultants some 
of whom felt that injectors might not return for the second appointment. It was also 
recognised that many injectors already have a follow up visit to their TSP after a positive 
result in order to have further blood tests, such as LFTs. We suggested there was 
sufficient overlap between 4.1 and 4.3 to merge these guidelines into a single statement: 
"Provide immediate counselling and assess other sources of support". This guideline 
would be part of the essential set.  
4.2 Support and information to prevent transmission to others should be provided 
This guideline was well understood by the majority of respondents. Test service 
providers indicated that they would always include this type of information when 
conducting post-test counselling for a positive result, and injectors also recognised its 
importance, although they indicated that the information might be better received at a 2nd 
appointment or through an organisation such as the HCCWA. It was felt that this 
information could be incorporated into the suggested two-stage positive result-giving, 
although this could be negotiated depending on the reaction of the injector to a positive 
result. It was considered that this guideline should be included as part of the essential set.   
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4.3 The extent of personal support should be assessed 
As outlined in the pre-test counselling, assessing the extent of someone's personal support 
was considered by most respondents to be an important, if complex, part of the testing 
process. As discussed previously, it was felt that in order to make the guidelines as 
simple and unambiguous as possible, it would be of benefit to merge this guideline with 
guideline 4.1 and to create a new guideline which read "Provide immediate counselling 
and assess other sources of support." This guideline would be part of the essential set.  
4.4 Referral to external sources of support such as longer-term counselling or a local 
Hepatitis C Council should occur 
The majority of injectors indicated that they would welcome referral for further support 
or information and most health professionals indicated that they also saw this as 
desirable, particularly in terms of providing further information. Some TSPs, however, 
expressed reservations about referring people for counselling, believing that this was 
better achieved "in house." Recognising the wide range of potential reactions to a positive 
diagnosis, and the varying level of skills which TSPs might have in responding to this, it 
was considered appropriate for this guideline to be negotiated based on the person's 
testing history, relationship with the TSP and current situation.  
Feedback on Suggested Modifications to the Guidelines 
This section summarises the results of the two focus groups which were run to provide 
feedback on these proposed changes. The focus group results were compiled and given to 
the consultants for further comments. 
The proposed modifications and feedback from the two focus groups and the consultants 
on these proposals are outlined below. 
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Focus Groups’ and Consultants’ Responses to Proposed Modifications to 
Guidelines 
 
NHMRC Guideline 1.1 




Focus Group 1 
Health Professionals 






of the minimal 
set of 
guidelines 
Need to check whether IV 
user, whether sharing 
equipment, what client’s 
knowledge re. BBVs is, 
what services they have 
accessed previously.  
Ask client why they want a 
BBV test. 
Essential to retain this 
guideline.  
Other suggestions were; 
include example questions 
on how to assess risk, 
encourage self-assessment 
and suggest how this could 
be done. Clients should be 
informed that they don’t 
have to answer questions. 
Agree.  
There is currently a 
lack of education for 
GPs in relation to 
assessing risk in a 
non-threatening, non-
judgemental way.  
 
 
NHMRC Guideline 1.2 
Pre-test counselling should provide clinical information about the virus 
Suggested Changes 
(NDRI) 
Focus Group 1 
Health Professionals 
Focus Group 2 
 Injectors 
Consultants 
Keep this guideline.  
Negotiate how much 
clinical information is 
provided based on the 
person’s testing history 
and their knowledge of 
BBVs 
Essential for new users. 
May need to do this before 
assessment 
Check the need to provide 
information. 
Essential that this guideline be
retained while allowing 
negotiation between client 
and TSP about how much 
information is provided based 
on the person’s testing history 
and their knowledge of BBVs.
No specific 
feedback on this 
guideline.  
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NHMRC Guidelines 1.4/1.5 
Pre-test counselling should provide information about the test and the possible 
consequences of testing, including confidentiality and notifiability/ provide 
information on testing benefits 
Suggested Changes (NDRI) Focus Group 1 
Health Professionals 
Focus Group 2  
Injectors 
Consultants 
Merge guidelines to create a 
new guideline. 
“Provide information about the 
test and the possible 
consequences and benefits of 
testing including confidentiality 
and notifiability.” 
Essential: part of the minimal 
set of guidelines. 
Provide some information 
at pre-test but go into more 
detail later: clients are often 
more responsive when they 







Needs to be retained. 
No objection to 
merging guidelines. 
It would be good 
to give injectors 
information about 
this so they can 
ensure their TSP 
covers it.  
 
NHMRC Guidelines 1.6/1.3 
Pre-test counselling should establish the ability to give informed consent / enable the 
patient to decide whether they should be tested 
Suggested Changes 
(NDRI) 
Focus Group 1 
Health Professionals 
Focus Group 2  
Injectors 
Consultants 
Merge these guidelines 
and create a new 
guideline. 
“Discuss whether the 
patient is ready and able 
to give informed consent. 
Gain informed consent.” 
Essential: part of the 
minimal set of guidelines. 
Guidelines could state 
“Have you obtained 
informed consent?” 
Needs to be retained 
as essential part of 
minimum set of 
guidelines. 




(not just for BBVs). 
Agree.  
Another issue to 
consider is that if results 
from an LFT are 
abnormal, the GP can 
order an additional test 
from the lab without 
having to seek further 
consent from their 
patient.  
 
NHMRC Guideline 1.7 
Pre-test counselling should identify support available to the patient  
Suggested Changes 
(NDRI) 
Focus Group 1 
Health Professionals 
Focus Group 2  
Injectors 
Consultants 
Keep this guideline.  
Negotiate whether this 
guideline is covered based 
on the person’s testing 
history, relationship with 
the TSP and current 
This guideline should be 
retained.  
Most important if client 
expresses poor coping 
mechanisms. 
This is an optional guideline 
which could be included with 
the first guideline re. 
assessing risk 
Important to identify third 
party support options, eg. 
Could read “In 
the event of a 
positive result, 
identify support.” 
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situation. Hepatitis C Council. 
NHMRC Guideline 1.8 
A written summary of the information covered in the pre-test counselling should be 
given, preferably in their native language 
Suggested Changes 
(NDRI) 
Focus Group 1 
Health Professionals 
Focus Group 2  
Injectors 
Consultants 
Keep this guideline.  
Negotiate whether written 
information is provided 
based on the person’s 
testing history and 
knowledge about BBVs. 
TSP could go to the relevant 
web site and give client a 
copy of information 
obtained 
Could provide a small 
leaflet which is not too 
obtrusive 
Essential for first test 
then negotiable 
Also important to consider 
what information about 
BBVs is available in a 
translated form and how 
culturally appropriate the 
information is .  
 
NHMRC Guideline 1.9 




Focus Group 1 
Health Professionals 
Focus Group 2  
Injectors 
Consultants 
Keep this guideline.  
Essential part of the 
“minimal set” of 
guidelines.  
Provide option to bring 
support person to post-test 
appt. 
Yes. Most important.  Essential that the 
guideline is kept, that it 
is part of a minimal set 
of guidelines and that 
the client be given the 
option to bring a support 
person. 
Face to face result 
giving is not always 
practical in rural and 
remote areas.  
 
 
NHMRC Guideline 2.1 
Post-test counselling should always be in person no matter what the reason for the 
test or whether the result is positive or negative.  
Suggested Changes 
(NDRI) 
Focus Group 1 
Health Professionals 
Focus Group 2 
 Injectors 
Consultants 
Keep this guideline.  
Essential: part of a 
“minimal set” of 
guidelines. 
Important in order to 
maintain contact after an 
indeterminate or negative 
result, as well as a positive 
result. 
Retain guideline. 
Appointment to be 
made at the 
conclusion of the 
test appointment 
Face to face result giving is not 
always practical in rural and 
remote areas. 
Delete 2.1. 2.2 and 2.3 and just 
have positive or negative results. 
If 2.1, 2.2 and 2.3 are deleted 
then consideration needs to be 
given to counselling for an 
indeterminate or equivocal result. 
Counselling in this situation 
should be couched appropriately 
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according to the individual, their 
level of risk and the likelihood of 
a positive or negative result.  
NHMRC Guideline 2.2 
Post-test counselling should ensure that the patient understands the meaning and 
implications of the test result 
Suggested Changes 
(NDRI) 
Focus Group 1 
Health Professionals 
Focus Group 2 
Injectors 
Consultants 
Keep this guideline.  
Negotiate based on the 
person’s testing 
history, relationship 
with the TSP and 
current situation. 
Could be covered in pre-test 
counselling.  
TSP needs to have an 
understanding of client’s level 
of understanding re testing. 
Could be negotiable, as long 
as it covered their 
understanding in the pre-test. 
This should be less based on 
TSP’s lack of time and more 
based on the client’s level of 
confidence. 
Retain guideline. 
Should be used to 
assess level of 
understanding. 
Delete 2.1. 2.2 and 2.3 and 
just have positive or 
negative results.  
If 2.1, 2.2 and 2.3 are 
deleted then consideration 
needs to be given to 
counselling for an 
indeterminate or equivocal 
result. Counselling in this 
situation should be couched 
appropriately according to 
the individual, their level of 
risk and the likelihood of a 
positive or negative result. 
 
NHMRC Guideline 2.3 
Post-test counselling should ensure that appropriate referrals and psychosocial 
interventions occur if required 
Suggested Changes 
(NDRI) 
Focus Group 1 
 Health Professionals 
Focus Group 2 
 Injectors 
Consultants 
Keep this guideline. 
Essential: part of the 
minimal set of 
guidelines. 
Delete this guideline as it is 
covered in the guidelines 
relating specifically to a 
positive or negative result.  
Reword to the following:
Ensure that appropriate 
referrals (eg 
psychosocial support) 
occur if requested or 
deemed necessary.  
Retain guideline as an 
essential part of 
minimum set of 
guidelines. 
 Delete 2.1. 2.2 and 2.3 
and just have positive or 
negative results.  
If 2.1, 2.2 and 2.3 are 
deleted then consideration 
needs to be given to 
counselling for an 
indeterminate or equivocal 
result. Counselling in this 
situation should be 
couched appropriately 
according to the 
individual, their level of 
risk and the likelihood of a 
positive or negative result. 
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NHMRC Guideline 3.1, 3.2 
Post-test for a negative result: Counselling should provide information to prevent 
exposure to the virus.  
The individual should be assisted to adopt relevant skills to remain infection free. 
Suggested Changes 
(NDRI) 
Focus Group 1 
Health Professionals 
Focus Group 2  
Injectors 
Consultants 
Keep this guideline. 
Essential: part of the 
“minimal set” of 
guidelines. 
Should the discussion be
based on the risk 
assessment from pre-test
discussion? 
Discussion should be 
based on pre-test risk 
assessment. 
Documentation of pre-test 
assessment therefore 
important. 
Aim to raise client’s 
knowledge re risk. 
Reword to the following: 
“Discussion should provide 
harm reduction information to 
prevent exposure to the virus 
and the individual should be 
assisted to remain infection 
free.” 
Retain the guideline. 
Important to determine why the 
patient is getting the test. If risk 
behaviour is to continue then 
harm reduction practices should 
be explored. 
No specific 
feedback on this 
guideline.  
 
NHMRC Guideline 4.1 /4.3 
Post-test for a positive result: Immediate counselling should be provided /the extent 
of personal support should be assessed. 
Suggested Changes 
(NDRI) 
Focus Group 1 
Health Professionals 




guidelines and create a 
new guideline. 
“Provide immediate 
support and assess 
other sources of 
support.” 
Essential: part of the 
“minimal set” of 
guidelines.  
 Have two stage 
positive result giving. 
The first stage would 
include immediate 
counselling and 
second stage would 
include medical and 
other consultations 
and referral.  
Use the merged 
guidelines.  
The 2 stage positive result 
giving depends on client. 
Give brochure and results 
to consider before next 
appointment.  
This guideline could 
include the last two 
guidelines re. transmission 
to others and referral to 
external sources of 
support. 
Query about the 
suitability of the word 
“counselling.” 
These two guidelines 
represent two separate 
issues and should not 
be merged. Also both 
should be retained as 
part of the minimal set 
of guidelines 
Opinion was divided about 
whether “pre- and post-test 
discussion” was the best term 
to replace “pre- and post-test 
counselling.” 
In post-test for a positive 
result, “counselling” could be 
used in its ‘proper’ term, but 
this distinction needs to be 
made clear.  
2 stage result giving is 
essential – encourage patients 
to bring someone to 1st and 
2nd appointment, write down 
questions which occur 
between appointments and 
ring the HCCWA between the 
appointments.  
2nd appointment would 
probably happen anyway in 
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order to do LFTs etc.  
NHMRC Guideline 4.2 
Post-test for a positive result: Support and information to prevent transmission 
should be provided 
Suggested Changes 
(NDRI) 
Focus Group 1 
Health Professionals 
Focus Group 2 Injectors Consultants 
Keep this guideline.  
Essential: part of the 
minimal set of 
guidelines.  
Incorporate into two 
stage positive result 
giving, though this 
could be negotiated 
depending on the 
reaction/state of the 
injector. 
Could be included under 
guidelines 4.1 and 4.2.  
Reword to the following: 
‘if positive, support, 
information and referral to 
prevent transmission to others 
should be provided.”  
Retain Guideline and include as 
essential. 
No specific feedback 
on this guideline. 
 
NHMRC Guideline 4.4  
Post-test for a positive result: Referral to external sources of support such as longer 
term counselling or a local hepatitis C Council should occur 
Suggested Changes 
(NDRI) 
Focus Group 1 
 Health Professionals 
Focus Group 2  
Injectors 
Consultants 
 Keep this guideline.  
Negotiate based on the 
person’s testing 
history, relationship 
with the TSP and 
current situation. 
Could be included under 
guidelines 4.1 and 4.2.  
The word counselling could be 
changed to discussion. 
Retain the guideline. Guideline 
should be negotiated based on 
person’s testing history, 
relationship with TSP and 
current situation. 
No specific 
feedback on this 
guideline. 
 
Summary of Responses to Proposed Modifications  
In summarising the responses, it is clear that there is strong agreement about the changes 
proposed to pre-test counselling guidelines, with the exception of the level of detail 
provided under guidelines 1.4 and 1.5 and some differences about the best placement of 
guideline 1.7. 
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In relation to the post-test counselling guidelines which apply whether the result is 
positive or negative both focus groups agreed that guidelines 2.1and 2.2 should be 
retained. Differences were expressed about guideline 2.3, with the first focus group 
indicating that this guideline could be incorporated into other guidelines and the second 
focus group indicating that it should be retained and reworded. Some consultants felt 
strongly that there needed to be an additional guideline for use in cases of indeterminate 
results.  
In relation to post-test counselling for a positive result, both focus groups agreed that the 
guidelines need to be retained and reworded. Both groups suggested that this area of the 
guidelines could be expanded.  
Where the focus groups differed most was in relation to post-test counselling for a 
negative result. The first focus group felt that these guidelines could be incorporated into 
one guideline. The second focus group felt that guidelines 4.1 and 4.3 should be kept 
separate and that the guidelines for 4.2 and 4.4 should be retained and possibly reworded. 
The key difference between the focus groups appeared to be that TSPs felt that post-test 
counselling for a negative result could be accomplished using one guideline, whereas 
people who injected drugs felt that post-test counselling for negative result required a 
more in-depth approach. 
The consultants agreed with the majority of suggested guideline changes. Most of their 
comments related to the implications of implementing changes to the guidelines, or ways 
to extend the suggested changes. The only significant area of difference between 
consultants was the merit of the term “pre- and post-test discussion” in preference to 
“pre- and post-test counselling”. We feel that ‘discussion’ is a preferable term, because of 
the multiple associations of the word counselling. This issue is discussed in more depth 
later.  
We have taken all these points into consideration in our final proposals for modifications 
to the existing NHMRC Guidelines for hepatitis C testing. Moreover, we consider that 
the modified guidelines should be generalised to all blood borne virus testing with 
injectors, since most tests occur in batteries rather than singly. Our proposed guidelines, 
therefore, relate to BBV testing with injectors.  
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Table 1: Proposed Guidelines for BBV Testing with Injectors 
Pre-test discussion should always be in person no matter what the reason for the test. Pre-test discussion aims to provide the individual with the 
information, ability and opportunity to give informed consent to the BBV test. 
At first test At subsequent tests 
Essential1 Essential1 Negotiable2 
 Provide clinical information about the virus  Assess risk 
Include exemplars for assessing risk 
 Provide clinical information about the 
virus 
 Assess risk 
Include exemplars for assessing risk 
 Provide information about the test and the 
possible consequences and benefits of 
testing including confidentiality and 
notifiability 
 Identify support available to the 
patient. 
 Provide information about the test and the possible 
consequences and benefits of testing including confidentiality 
and notifiability 
 Discuss whether the patient is ready and 
able to give informed consent. Gain 
informed consent  
 Provide additional information about 
the virus  
Format and language of information 
should be appropriate to the person’s 
literacy and language skills. 
 Provide additional information about the virus  
Format and language of information should be appropriate to the 
person’s literacy and language skills.  
 Arrange the post test discussion  
Provide option to bring a support person when 
receiving results. 
 
 Discuss whether the patient is ready and able to give 
informed consent. Gain informed consent  
 
 Identify support available to the patient. 
  
 Arrange the post-test discussion 
Provide option to bring a support person when receiving results.   
1Essential; these guidelines should be included in every pre- and post-test  discussion regardless of the person's testing history, relationship with TSP, knowledge of blood borne viruses or current situation. 
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2Negotiable: these guidelines could be negotiated between the person being tested and the test service provider based on the person's testing history, relationship with TSP, knowledge of blood borne viruses or current 
situation. 
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Post-test discussion should always be in person no matter what the reason for the test or whether the result is positive or negative. The purpose 
of post-test discussion is to ensure the individual understands the meaning and implications of the test result and is provided with support, 
information and referral as appropriate.  
Negative result Positive result 
Essential Essential Negotiable 
 Facilitate discussion which provides harm reduction 
information to prevent exposure to the virus. Assist the person 
to develop skills in remaining infection free.  
Discussion should be based on the pre-test risk assessment.  
 Provide immediate counselling and 
assess other sources of support 
Incorporate positive result giving into two 
stages as appropriate. It is recommended 
that this guideline be addressed at the 1st 
appointment.  
 Refer to external sources of support 
such as longer-term counselling or a 
local Hepatitis C Council  
Incorporate into two stage positive result 
giving as appropriate. It is recommended 
that this guideline be covered at the 1st 
and/or 2nd appointment  
 
• Provide support and information to 
prevent transmission  
Incorporate positive result giving into two 
stages as appropriate. It is recommended 




Discussions in this situation should be couched appropriately according to the individual, their level of risk and the likelihood of a positive or negative result. 
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Other Issues Relating to NHMRC Guidelines  
In addition to providing feedback on specific guidelines, the focus groups and 
consultants made additional comments about other issues related to pre- and post-test 
discussion.  
Focus group one comprised a number of TSPs from rural areas, and their comments 
related to the implications in rural areas of limited access to testing facilities, the 
financial cost of a blood borne virus test, collection and transporting fees for 
specimens and the confidentiality of results. This was verified by one of the 
consultants, who indicated that GPs who did not bulk bill tended not to ask 
laboratories to bulk bill. If there was a higher percentage of GPs in rural areas who did 
not bulk bill, this could account for the difficulties identified by focus group one.  
Comments from focus group two, who represented injectors, were mainly related to 
the relationship between TSPs and injectors, which was seen as very important. 
Participants believed that injectors who did not have a regular GP were less likely to 
receive pre- and post-test discussion according to the Guidelines. They suggested that 
a checklist for injectors might help remind them which questions they should ask their 
TSP, although they felt that disseminating such a list could be difficult. The 
consultants supported this concept, indicating that it would be in accordance with 
current developments in GP/patient relationships in terms of providing patients with 
the means to ask more questions of their GP. It was suggested that this checklist could 
take the form of a poster and/or a pamphlet.  
Participants in the second focus group also suggested that TSPs should have a list of 
Frequently Asked Questions about BBV testing so that they knew what to expect and 
could have appropriate information on hand. 
The consultants had a number of suggestions about the language used in the revised 
guidelines. It was suggested that the guidelines should be written as action statements, 
with an additional checklist of exemplars to which TSPs could refer. The consultants 
also recognised that definitions needed to be included for terms such as “indeterminate 
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result” and “harm reduction.” The term “counselling” needed to be used clearly and 
consistently, or be replaced with an alternative term.  
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DISCUSSION  
The proposed guidelines encapsulate the data that has been gathered in this study. In 
this section, we take up some issues which we believe warrant further consideration, 
discuss implementation of the proposed guidelines and make some specific 
recommendations.  
ISSUES RELATING TO THE MODIFIED GUIDELINES 
Risk Assessment  
As noted above, both injectors and TSPs identified that assessing risk was an 
important part of pre-test counselling and recognised that risk practices and knowledge 
about BBV transmission might vary over time. Injectors, however, believed that risk 
assessment should go beyond merely establishing whether the client was a drug 
injector. Their specific risk behaviours, occasions of risk, their own assessment of the 
risk of sharing injecting equipment with close friends and lovers, and the likelihood of 
domestic transmission in households with at least one positive member could all be 
discussed.  
This risk assessment, if detailed enough, can be an opportunity for occasions of risk to 
be examined in detail once the test result is known. It is also an opportunity to explore 
patterns of greatest risk – such as being intoxicated –and discuss ways to reduce risk at 
these times. Tested injectors said they would value these discussions as long as they 
were not presented as lectures, and conveyed information that was new. Some TSPs, 
however, questioned whether they had enough time to conduct these detailed risk 
assessments – this issue is taken up in more detail below.  
Repeat Testing  
This study shows that much BBV testing of injectors is undertaken at the injector’s 
request and that many injectors and TSPs felt that TSPs should acquiesce to every test 
request. Test service providers have good reasons for doing so including creating 
opportunities for harm reduction information dissemination and building and 
maintaining rapport with their patients. Nevertheless, it is clear both from this and our 
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earlier study (Loxley et al., 1999) that some injectors request regular testing less to 
establish whether they have become infected, than to demonstrate that they are 
‘clean”. That this motivation is unlikely to be conducive to behaviour change was 
demonstrated in the first study. Nevertheless, testing can alter risky behaviour as has 
been clearly demonstrated in the present study.  
Given the public health resources that are involved in testing, we believe that TSPs 
should make decisions about the frequency of testing on clinical grounds, and 
negotiate these with individual patients. Injectors should be required to demonstrate 
that there are sufficient grounds for retesting (eg new episodes of risky behaviour) and 
if testing does not appear to change behaviour, discussions between the TSP and the 
patient about the purpose of testing should ensue.  
Confidentiality and Notifiability  
In the modified guidelines we suggested that establishing whether the patient was 
ready and able to give informed consent should be the major task of pre-test 
counselling. This included being given information about the virus, the infection and 
the test, not only in terms of what test results meant but also what could and would 
happen to test results. Patients have a right to know what use can be made with 
information about themselves. This is in line with the NHMRC Ethical Conduct in 
Research Statement which clarifies that consent should be sought for the disclosure of 
personal information whenever possible (NHMRC, 1999).  
While giving patients information about confidentiality has been found to be hardly 
contentious because it reassures patients who come for testing, we understand the 
concerns that some TSPs have that giving information about the notifiability of 
positive results may unnecessarily worry some patients. Nevertheless, none of the 
injectors in this study who were told about notifiability for the first time in the 
research process were inappropriately concerned about it, nor did any of them feel that 
if they had been told in the testing process it would have discouraged them from being 
tested. Indeed, some were indignant that they had not been told, indicating that it felt 
as if health authorities had something to hide.  
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These matters are best resolved in pre-test discussions between a patient and a TSP 
who have a good relationship. If the injector is unwilling to given consent to a medical 
procedure because they do not trust their health professional, referral to an alternative 
test provider should be considered.  
Giving Test Results  
The majority of TSPs in this study gave all BBV test results in person, and the 
majority of injectors received their last results in person. Nevertheless, it is 
disappointing to note that, despite very clear Guidelines to the contrary, some TSPs 
gave hepatitis results over the phone, and/or felt that negative results did not warrant 
return visits.  
This goes to heart of whether a BBV test with an injector is solely a medical 
intervention, designed to diagnose an infection which, if it present, can be treated, or 
whether it is also an effective brief psychosocial intervention to prevent infection. The 
NHMRC Guidelines make it clear that it should be considered as the latter. We will 
return to this point later.  
There was strong support in this study for the practice of making the follow-up 
appointment at the pre-test appointment. This obviates the necessity for the medical 
practice to ring the patient to make a follow-up appointment, with all the anxiety that 
may engender. Moreover it makes it abundantly clear to the injector that they should 
expect post-test discussion, whatever the test result. With that expectation, they are 
more likely to be willing to participate in effective post-test discussions of both 
negative and positive results.  
Follow-up with Positive Results  
The discussion of medical options following positive test results is obviously an 
important consideration, but post-test discussion after a positive result should be more 
than a medical intervention. Some TSPs may underestimate how devastating a positive 
hepatitis test result can be. Injectors in both this study and our earlier research 
graphically demonstrated that a positive result could feel at first like a death sentence. 
Given this, and the need to intervene both medically, and behaviourally to prevent 
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further transmission, we strongly recommend that whenever resources allow and the 
patient is willing, the TSP should schedule a second appointment after a positive 
result, and devote the first appointment to giving support and reassurance. Moreover, 
patients should be encouraged to bring their own support people with them to collect 
results. Referral to other support service such as hepatitis C councils should, wherever 
possible, be made.  
The readiness to refer to other agencies when one cannot provide a service oneself is a 
fundamental element of clinical practice across many disciplines. Referral does not 
necessarily mean giving up on a relationship with a client in order to send them off 
somewhere else: indeed many clinicians note that it can be just as hard to initiate and 
resource an appropriate referral as it is to provide a service oneself. Clearly, one needs 
to know who is available as referral sources, how these can be accessed and what they 
can offer. Good use can be made of the referral sources available to TSPs such as 
community based drug users’ groups and hepatitis C councils. The question of the 
ability of organisations such as these to support referrals is, however, one that they 
will have to resolve in consultation with the medical community. 
PRE- AND POST-TEST ‘COUNSELLING’  
We have used the term ‘counselling’ consistently through the research and in this 
report4, because it is the standard term that was first used to refer to pre- and post-
testing discussion for HIV/AIDS tests and continues to be applied to hepatitis testing.  
It may not, however, be the most appropriate term. In our first study we found some 
confusion on the part of injectors between pre- and post-test ‘counselling’ and 
therapeutic counselling and that confusion was also evident in the present study. Of 
more significance, perhaps, is whether this is the appropriate term to use for 
interactions which may not seem to either party to be so much counselling as 
discussion and negotiation.  
The recent Draft National Hepatitis C Testing Policy (2001) recommends the term 
‘test discussion’ for the pre-test session because the term counselling is not broad 
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enough to encompass the various elements: assessment of risk, obtaining of informed 
consent, arranging follow-up and identification of referral needs. We would concur 
with this view, but propose that this session be defined as ‘pre-test discussion’ so that 
patients are aware that all of this would take place before the test is undertaken. The 
Draft National Hepatitis C Testing Policy uses the term ‘post-test counselling’ for all 
post-test interventions, both for negative and positive tests; again, we feel that 
‘counselling’ is not a broad enough term to cover the elements that will be broached. 
‘Post-test discussion’ is a better descriptor.   
Use of the terms ‘pre- and post-test discussions’ should thus reduce confusion, more 
accurately reflect the focus of these sessions, and may also defuse any concern or 
anxiety on the part of either party as to what might be expected from ‘counselling’.  
The issue of whether or not TSPs have enough time to follow the testing guidelines is 
one that was raised a number of times by both injectors and TSPs themselves. If the 
proposed guidelines were followed, a number of discussions would be shorter than 
they would be with the current NHMRC Guidelines, because some discussion topics 
would be negotiated and might be omitted.  
Finally, we can only reiterate what we have said before. Blood borne virus testing with 
injectors is an important opportunity for brief interventions to reduce risk to 
individuals and the community. TSPs who feel unable to offer complete pre- and post-
test discussions because of lack of time, should discuss this with their injector patients 
and negotiate what can be undertaken.  
IMPLEMENTATION ISSUES  
Our research demonstrates that implementation is a concern: test service providers are 
busy people who are bombarded with invitations to training exercises, and sent 
extraordinary amounts of paper resources to consider. Nevertheless, these or any other 
guidelines will not be effective unless TSPs are aware of them and receive some 
support in their implementation. How this is to be undertaken will be a matter for 
medical organisations to determine. Clearly some TSPs, perhaps particularly those in 
                                                                                                                                            
4 Other than in the proposed guidelines 
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rural and regional areas, will need extra support. It appears that the form of the 
guidelines – paper, internet, CD etc – may be less important than the usefulness of the 
guidelines and the preparedness to use them.  
A further strategy would be to inform injectors about what they could expect when 
they request BBV testing. We found that the majority of our injector respondents did 
not know that guidelines for pre- and post-test counselling existed, and many were 
impressed with the scope of these when they were so informed. Material which 
explains the guidelines could be prepared, and made available through the various 
community based and medical services with which injectors have contact. That way, 
many injectors could be well prepared for their test: might understand that a BBV test 
was more than a quick check, and might be more willing to work together with their 
TSP to negotiate a testing process which was most suited to their individual needs. A 
checklist for injectors to remind them which questions they should ask their TSP could 
be appended to those materials. TSPs could have a Frequently Asked Questions list 
attached to the guidelines to remind them of the issues that are likely to be of most 
concern to injectors. 
The availability and appropriateness of materials which have been translated into other 
languages and about the provision of information for people with low literacy levels 
was a more general concern. This is an issue which warrants further attention. 
SPECIFIC RECOMMENDATIONS 
While most of our recommendations are contained in the proposed guidelines, and the 
issues discussed above, there are a few specific tasks which we believe should be 
undertaken:  
1. It was suggested that the proposed guidelines should be written as action 
statements, with an additional checklist of exemplars to which TSPs could refer. 
This seems like an excellent suggestion, but we believe it could best be undertaken 
by people with medical qualifications who have full understanding of clinical 
issues.  
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2. We have suggested that a manual or brochure for injectors should be developed: 
this, again, would best be undertaken by peers who understand the particular issues 
that confront injectors.  
3. Sensitivity about phlebotomy has emerged as a somewhat unexpected concern in 
this study. We recommend that this issue be raised with TSPs in discussions and 
written material relating to the guidelines.  
4. Rates of hepatitis B vaccination apparently increased between the first and second 
studies in this series. This appears to relate to the greater availability of free 
vaccine in WA, and the commencement of a free vaccination program at WASUA. 
Cost is one of the major barriers to vaccination - we recommend that States and 
Territories consider how they can best offer free vaccination to at-risk populations 
like drug injectors until universal vaccination programs take effect in the 
community.  
CONCLUSION 
As we noted in the Introduction, hepatitis testing can be used to assist those tested to 
become aware of the extent of the epidemics, the prognosis of infection, and the 
realistic likelihood of becoming infected, reflect upon their risk behaviour, and 
develop strategies to minimise it, thus reducing the risk of infection. Our research 
generally supports this contention. BBV testing of injectors can be a good opportunity 
for prevention but it does not automatically follow that it will be, or that it currently is. 
Since the majority of injectors are tested at some point and many have multiple tests 
and often have multiple contacts with TSPs, testing is an excellent opportunity for 
brief interventions with a large number of at risk people.  
With a clear statement of the value of appropriate pre- and post-test discussions, 
injectors and TSPs will find the testing experience valuable. The best testing 
experiences will undoubtedly be those that emerge from a relationship of rapport and 
mutual respect between the injector and his/her TSP. These relationships will not 
always be easy to develop, but our research shows that they exist and can be 
developed.  
It is axiomatic, however, that a test event is a not only a medical but also a 
psychosocial intervention to prevent risk behaviour. Both injectors and TSPs need to 
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have the expectation that a test event is an opportunity for them to discuss why the 
injector could be infected and how further risk to the individual and the community 
could be avoided.  
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